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Abstract
Brain and spinal stimulation therapies for phantom limb
pain: a systematic review
Mark Corbett,1* Emily South,1 Melissa Harden,1 Sam Eldabe,2
Erlick Pereira,3 Imad Sedki,4 Neil Hall2 and Nerys Woolacott1
1Centre for Reviews and Dissemination (CRD), University of York, York, UK
2James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesborough, UK
3Academic Neurosurgery Unit, St George’s, University of London, London, UK
4Royal National Orthopaedic Hospital, Stanmore, UK
*Corresponding author mark.corbett@york.ac.uk
Background: Although many treatments exist for phantom limb pain (PLP), the evidence supporting
them is limited and there are no guidelines for PLP management. Brain and spinal cord neurostimulation
therapies are targeted at patients with chronic PLP but have yet to be systematically reviewed.
Objective: To determine which types of brain and spinal stimulation therapy appear to be the best for
treating chronic PLP.
Design: Systematic reviews of effectiveness and epidemiology studies, and a survey of NHS practice.
Population: All patients with PLP.
Interventions: Invasive interventions – deep brain stimulation (DBS), motor cortex stimulation (MCS),
spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation. Non-invasive interventions –
repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).
Main outcome measures: Phantom limb pain and quality of life.
Data sources: Twelve databases (including MEDLINE and EMBASE) and clinical trial registries were
searched in May 2017, with no date limits applied.
Review methods: Two reviewers screened titles and abstracts and full texts. Data extraction and quality
assessments were undertaken by one reviewer and checked by another. A questionnaire was distributed to
clinicians via established e-mail lists of two relevant clinical societies. All results were presented narratively
with accompanying tables.
Results: Seven randomised controlled trials (RCTs), 30 non-comparative group studies, 18 case reports and
21 epidemiology studies were included. Results from a good-quality RCT suggested short-term benefits of
rTMS in reducing PLP, but not in reducing anxiety or depression. Small randomised trials of tDCS suggested
the possibility of modest, short-term reductions in PLP. No RCTs of invasive therapies were identified.
Results from small, non-comparative group studies suggested that, although many patients benefited from
short-term pain reduction, far fewer maintained their benefits. Most studies had important methodological
or reporting limitations and few studies reported quality-of-life data. The evidence on prognostic factors
for the development of chronic PLP from the longitudinal studies also had important limitations. The results
from these studies suggested that pre-amputation pain and early PLP intensity are good predictors of
chronic PLP. Results from the cross-sectional studies suggested that the proportion of patients with severe
chronic PLP is between around 30% and 40% of the chronic PLP population, and that around one-quarter
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of chronic PLP patients find their PLP to be either moderately or severely limiting or bothersome. There were
37 responses to the questionnaire distributed to clinicians. SCS and DRG stimulation are frequently used
in the NHS but the prevalence of use of DBS and MCS was low. Most responders considered SCS and
DRG stimulation to be at least sometimes effective. Neurosurgeons had mixed views on DBS, but most
considered MCS to rarely be effective. Most clinicians thought that a randomised trial design could be
successfully used to study neurostimulation therapies.
Limitation: There was a lack of robust research studies.
Conclusions: Currently available studies of the efficacy, effectiveness and safety of neurostimulation
treatments do not provide robust, reliable results. Therefore, it is uncertain which treatments are best
for chronic PLP.
Future work: Randomised crossover trials, randomised N-of-1 trials and prospective registry trials are
viable study designs for future research.
Study registration: The study is registered as PROSPERO CRD42017065387.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Phantom limb pain (PLP) is pain perceived by amputees in the missing part of their limb. Electricalstimulation of the brain or spine can be used to treat long-term PLP when other treatments have not
worked, but there is limited knowledge on how effective it is. Brain stimulation can be non-invasive
(electrodes placed on the scalp) or invasive (electrodes inserted into the brain during an operation).
Stimulation of the spine is an invasive therapy. This project aimed to find out which types of brain and
spine stimulation seem likely to be best for treating PLP.
We identified and studied all the key data from all relevant research publications and also asked NHS
clinicians for their views. Results from studies of non-invasive brain stimulation treatments showed that
they may improve PLP for a short time after treatment, but there were no long-term data. Results
from studies of invasive stimulation treatments suggested that, although many patients benefited from
short-term pain reduction, far fewer had long-term benefit.
Other types of study showed that around one-quarter of patients with chronic PLP found their pain to
be either moderately or severely limiting or bothersome. The survey of clinicians suggested that spinal
stimulation is often used for PLP in the NHS, with most of the clinicians considering it to be at least
sometimes effective. There were fewer positive views on how well brain stimulation worked.
Based on all these findings, specific recommendations were made for conducting future research studies
that should produce much more reliable results.
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Scientific summary
Background
Phantom limb pain (PLP) is defined as persistent painful sensations perceived in the missing portion of an
amputated limb. It is experienced by around 60–80% of amputees but the intensity, frequency, nature
and duration of PLP can vary widely. There appears to be no single best treatment for PLP, although the
options are numerous and varied. A pharmacological focus prevails in primary care settings, but patients
rarely report satisfactory pain management. Other interventions include transcutaneous electrical nerve
stimulation (TENS), acupuncture, mirror therapy, cognitive–behavioural therapy (CBT), perioperative
interventions, and myoelectric and body-powered prostheses.
Brain, spinal cord and dorsal root ganglion (DRG) neuromodulation (or neurostimulation) therapies are
targeted at patients with chronic pain that is refractory to pharmacological treatment. Deep brain stimulation
(DBS) is a neurosurgical procedure in which electrodes are implanted into certain parts of the brain with
stimulation controlled by a pacemaker-like device, called a neurostimulator (implanted under the skin in the
chest or abdomen). The stimulation may alter the electrical signals in the brain that are responsible for pain.
Motor cortex stimulation (MCS) involves placing electrodes on the surface of the brain and is equally as
invasive as DBS. Non-invasive brain stimulation therapies, such as repetitive transcranial magnetic stimulation
(rTMS) and transcranial current stimulation, also exist. In spinal cord stimulation (SCS), and DRG stimulation,
electrodes are implanted near the spinal cord or the DRG and are connected to a neurostimulator. This
generates an electrical pulse, which can provide analgesia through different mechanisms. No fully systematic
review of neuromodulation therapies has previously been published; reviews of other PLP treatments report
that the evidence is generally limited. The combination of limited evidence and a lack of guidelines for the
management of PLP represents a major challenge for the clinician.
Objectives
The objective was to determine which types of brain and spinal stimulation therapy are likely to be the
most promising for treating chronic PLP. This was done by undertaking a systematic review to assess the
evidence on treatment effectiveness and safety and a systematic review of the epidemiology of chronic
PLP. A survey of practising NHS clinicians was also undertaken to obtain information on which treatments
are used to treat chronic PLP in the NHS and how effective they are perceived to be, and to elicit opinions
regarding future research studies.
Methods
Systematic reviews
A systematic review of the clinical literature on the effectiveness and safety of brain and spinal stimulation
therapies for PLP was undertaken and registered on PROSPERO (registration number CRD42017065387).
Searches were carried out during May 2017 using a broad search strategy, without date or language
restrictions. Twelve databases (including MEDLINE and EMBASE) were searched as well as several clinical
trial registries. Eligible studies were of patients with PLP resulting from amputation. For studies of
intervention effectiveness and safety, the eligible interventions were DBS, MCS, rTMS, transcranial current
stimulation, SCS (also referred to as dorsal column stimulation) and DRG stimulation. Any comparator
treatment was eligible. Studies had to report quantitative results on PLP intensity (either continuous or
categorical data). Only comparative trials were eligible for the non-invasive therapies, but uncontrolled
studies were also eligible for the invasive therapies.
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Studies that reported data relevant to the epidemiology of chronic PLP were also identified from the
same broad database search results. Eligible studies had to report data on the level or severity of PLP
(either continuous or categorical data). Studies also had to report using patient inclusion criteria of either
≥ 6 months since amputation or a mean or median time since amputation of ≥ 1 year. Prospective studies
that recruited patients prior to amputation were eligible if they reported relevant PLP data for ≥ 6 months
post amputation.
Two reviewers independently screened all titles and abstracts and full papers. Discrepancies were resolved by
consensus or via a third reviewer. Comparative trials were quality assessed using the Cochrane risk-of-bias
tool. Uncontrolled studies were quality assessed using specific items from the PROCESS (preferred reporting
of case series in surgery) checklist. Invasive surgical interventions were also evaluated based on key aspects
of the stages of Innovation, Development, Exploration, Assessment, and Long-term study (the IDEAL model).
Data extraction and quality assessments were conducted by one reviewer and checked by a second, with any
discrepancies resolved by discussion or via a third reviewer.
Data on patient characteristics, interventions and outcomes were tabulated and a narrative synthesis was
undertaken. Results were interpreted in the context of the results of study quality assessments. The possibility
of pooling randomised controlled trial (RCT) data using meta-analysis was explored, but was not possible
owing to heterogeneity of outcome data.
Survey
A questionnaire on the frequency of use of specific PLP treatments, their perceived effectiveness and the
viability of future research studies was distributed between September and November 2017 via the e-mail
lists of the British Society for Stereotactic and Functional Neurosurgery and the Neuromodulation Society
of the United Kingdom and Ireland. Results were analysed and presented narratively with accompanying
tables when appropriate (see Chapter 3, Results).
Results
Overall, 6082 titles and abstracts were screened for inclusion and the full texts of 303 papers were
assessed against the review eligibility criteria. Seven RCTs, 30 non-comparative group studies, 18 case
reports and 21 epidemiology studies were included.
Studies of efficacy, effectiveness and safety
Results from a randomised trial (with a low overall risk of bias) of 54 PLP patients suggested worthwhile
short-term benefits of rTMS in reducing PLP, but not in reducing anxiety or depression. However, the
PLP benefit seen 2 weeks after the end of treatment was no longer evident 4 weeks after the end of
treatment. The two other RCTs of rTMS were smaller; one had a very short follow-up duration and the
other had a high overall risk of bias. Small randomised trials of transcranial direct current stimulation
(tDCS) suggest the possibility of modest, short-term reductions in PLP. Both tDCS and rTMS appeared
safe in the short term.
All the evidence on invasive neuromodulation therapies was derived from uncontrolled group studies
(case series) or case reports. Overall, there were four group studies of MCS, eight of DBS, three of DRG
stimulation and 14 of SCS. Although several studies reported results that appeared impressive in the short
term, the effects diminished over time in some patients, with implants sometimes having to be removed.
Nevertheless, it appears that some patients do benefit in the longer term from invasive neuromodulation
therapies, although most studies did not have follow-up data beyond around 2 years.
Many of the non-comparative group studies had important methodological and/or reporting limitations.
All the studies were small, few studies recruited patients consecutively or used a prospective design and
only three studies were multicentred. Some studies did not present results for outcomes mentioned in their
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methods sections (so selective outcome reporting may have biased the study results) and few studies
reported data on outcomes important to patients, such as quality of life. Many publications reported on
mixed cohorts of patients, with some data not reported separately for the subgroup of patients with PLP.
Epidemiology
Eight epidemiology studies had a longitudinal design and 13 had a cross-sectional design. The evidence
on prognostic factors for the development of chronic PLP from the longitudinal studies had important
limitations, including small sample sizes and short follow-up durations. The longitudinal study results
suggested that both pre-amputation pain and early PLP intensity are good predictors of chronic PLP up
to 2 years after amputation. Neither level of amputation nor early stump pain seem to be correlated with
PLP intensity at later follow-ups.
Results from the cross-sectional studies suggested that the proportion of patients with severe chronic PLP
is between around 30% and 40% of the chronic PLP population, whereas the proportion of patients with
moderate chronic PLP is around 25%. From the studies reporting data on how chronic PLP affects patients’
daily lives, it appears that around one-quarter of chronic PLP patients find their PLP to be either moderately
or severely limiting or bothersome. Considerable variation was reported across studies regarding the
frequency and duration of PLP episodes. Although many of the cross-sectional studies had large sample
sizes, many also had participation rates of between around 50% and 70%. Therefore, it is possible that
the results of these studies were subject to non-response bias, which might limit their generalisability to
the broader chronic PLP population.
Survey
A total of 37 online questionnaire responses were received from 30 different hospitals: 67% from pain
management clinics, 30% from neurosurgery units and 3% from a rehabilitation unit. Most responders were
either pain physicians (62%) or neurosurgeons (30%). Results indicated a very high use of pharmacological
treatments in the chronic PLP population, with CBT and mirror therapy or graded motor imagery also being
frequently used. Of the invasive neuromodulation therapies, SCS and DRG stimulation were frequently used.
The prevalence of the use of DBS and MCS was quite low, as would be expected given the current lack of
NHS funding for these treatments.
Most clinicians considered pharmacological treatments and CBT to be at least sometimes effective for
chronic PLP. TENS was not thought to be very effective by most clinicians, but around two-thirds of
neurosurgeons considered acupuncture to sometimes be effective. Pain physicians considered mirror
therapy and graded motor imagery interventions to be more frequently effective than did neurosurgeons.
A large majority of responders considered SCS and DRG stimulation to be either mostly or sometimes
effective, but neurosurgeons were split in their opinions on how frequently DBS is effective. Most
neurosurgeons considered MCS to rarely be effective.
Nineteen of the 24 responders who had administered neuromodulation therapies thought that a
randomised trial design could be successfully used to study neuromodulation therapies for PLP. Problems
with patient recruitment were foreseen by two responders. Of the therapies that could be studied in a
RCT, pain physicians reported that they would most like to see SCS and DRG stimulation studied, whereas
neurosurgeons reported that they would most like to see DRG stimulation and DBS studied.
Conclusions
The studies of the efficacy, effectiveness and safety of neuromodulation treatments do not provide robust,
reliable results, largely owing to a combination of study design and reporting limitations, small sample sizes
and short follow-up durations. Consequently, there is much uncertainty about which neuromodulation
treatments are best for treating chronic PLP, hindering informed treatment decisions in clinical practice.
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Many of the epidemiological studies that included chronic PLP patients also yielded limited data, although
they indicated that PLP that substantially affects quality of life is not a rare condition. Although these data,
along with the views of NHS clinicians derived from our survey, suggest that recruitment to a randomised trial
may be viable, there are credible concerns (from neuromodulation studies of other types of chronic pain) that
recruitment and retention might be problematic. Randomised crossover or randomised N-of-1 trial designs
may be the most viable approaches. An alternative study design could be a prospective registry study that
incorporates N-of-1 trials. Among NHS clinicians, SCS, DRG stimulation and DBS were the interventions most
frequently chosen for evaluation in RCTs. Regardless of the study design adopted, long-term evaluation of
quality-of-life outcomes would be important, as would broader assessments of pain that go beyond pain
intensity alone.
Study registration
This study is registered as PROSPERO CRD42017065387.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Phantom limb pain (PLP) is defined as persistent painful sensations perceived in the missing portion ofan amputated limb. Common reasons for limb amputations include circulatory disorders, severe trauma
events, cancer and persistent limb infections. Although not fully understood, it is thought that PLP is
caused by cortical changes in the brain (i.e. by disorganised brain mapping), with alterations at other levels
of the central nervous system, such as the dorsal root ganglion (DRG), having a role.1 As the nerves heal
following amputation, the ‘wrong connections’ can be formed such that the sense of touch is perceived as
pain, and this in turn can result in central sensitisation.2,3
Postamputation phenomena can comprise three elements:4
1. phantom limb pain – painful sensations referred to the absent limb
2. phantom limb sensation – any sensation in the absent limb, except pain
3. stump pain – pain localised in the stump.
Phantom limb pain occurs in around 60% to 80% of amputees, but the intensity, frequency and duration
of PLP can vary widely.5 Risk factors have been reported to include female sex,6,7 pre-amputation pain8
and depression.9 PLP may be severe in around one-third of patients;9,10 however, for many patients, the
pain may be episodic and not particularly disabling. For example, in one survey, half of patients with PLP
reported one or fewer episodes of PLP per week, with most episodes lasting between a few minutes and
1 hour.10 Another survey reported that around one-fifth of patients always experience PLP.9 The presence,
duration and severity of PLP are, therefore, all-important determinants of health-related quality of life.11,12
There appears to be no single best treatment for PLP, although the options seem numerous and varied.
As far back as 1980, a literature review and survey identified 68 different methods of treating PLP, 50 of
which were still in use at that time.13 A pharmacological focus on treatment prevails in primary care settings,
although amputees with PLP rarely report satisfactory pain management.14 A recent systematic review15
of pharmacological interventions found the randomised trial evidence for the medications reviewed to be
inconclusive. This was mainly a result of the limited outcomes reported and the small trial sample sizes:
14 trials were identified, covering seven different types of treatment, and the total number of participants
across all trials was only 269 (sample sizes ranged from 8 to 36).15
Other treatments have also been studied in systematic reviews, although they are often based on
even more limited evidence. They include perioperative interventions,16 transcutaneous electrical nerve
stimulation (TENS),17,18 acupuncture,19 mirror therapy20 and myoelectric and body-powered prostheses.21
This combination of limited evidence and a lack of guidelines for the management of PLP represents a
major challenge for clinicians.
Brain, spinal cord and DRG neurostimulation therapies are targeted at patients with chronic pain that is
refractory to pharmacological treatment. Deep brain stimulation (DBS) is a neurosurgical procedure in which
electrodes are implanted into certain parts of the brain. The amount of stimulation the brain receives is
controlled by a pacemaker-like device, called a neurostimulator, which is implanted under the skin in the
chest or abdomen. The stimulation may alter the electrical signals in the brain that are responsible for pain.
Motor cortex stimulation (MCS) – a therapy that is equally as invasive as DBS – involves placing electrodes
on the surface of the brain. Other brain stimulation therapies are non-invasive, such as repetitive transcranial
magnetic stimulation (rTMS) and transcranial current stimulation.
In spinal cord stimulation (SCS) and DRG stimulation, electrodes are implanted near the spinal cord or the
DRG and connected to a neurostimulator that is inserted under the skin in the abdomen, chest wall or in the
buttock area. This generates an electrical pulse that can provide analgesia through different mechanisms.
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The National Institute for Health and Care Excellence (NICE)22,23 recommends that:
DBS should only be used in patients with refractory chronic pain syndromes that other treatments have
failed to control; patient selection should be carried out by a multidisciplinary team specialising in
pain management.
© NICE [2011] Deep Brain Stimulation for Refractory Chronic Pain Syndromes (Excluding Headache).22
Available from www.nice.org.uk/guidance/ipg382. All rights reserved. Subject to Notice of rights. NICE
guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular
review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in
this product/publication
SCS should only be used in adults with chronic pain of neuropathic origin if they continue to
experience chronic pain (measuring at least 50 mm on a 0–100 mm visual analogue scale) for at least
6 months despite appropriate conventional medical management and who have had a successful trial
of SCS. This is providing that patients are assessed by a multidisciplinary team experienced in chronic
pain assessment and management of people with SCS devices.
© NICE [2008] Spinal Cord Stimulation for Chronic Pain of Neuropathic or Ischaemic Origin.23 Available
from www.nice.org.uk/guidance/ta159. All rights reserved. Subject to Notice of rights. NICE guidance
is prepared for the National Health Service in England. All NICE guidance is subject to regular review
and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this
product/publication
Although there are other neurosurgical means of relieving PLP, such as dorsal root entry zone lesioning
(DREZ), these surgeries are irreversible and have higher-risk profiles. They should only be considered for
patients refractory to the reversible neurostimulation therapies outlined earlier in this section, and are
therefore beyond the scope of this review.
Scope of the existing research for stimulation therapies
In order to scope the need for further secondary research, we initially conducted a preliminary search
of the published literature. The results indicated that the evidence base for neurostimulation therapies
appeared limited.
Invasive brain stimulation therapies
There were no systematic reviews of studies of brain stimulation for PLP. Literature reviews of DBS in patients
with chronic pain conditions have included some small studies of PLP patients, with results suggesting
beneficial and clinically important pain reduction in some patients.24–26 However, these three studies were
not systematic reviews and the scope of the patient populations studied was broad. Consequently, the data
presented were sometimes limited in terms of intervention parameters, patient characteristics and results/
numbers of outcomes. This is important because there is no consensus on how DBS operations should be
undertaken – slight differences in surgical technique or postoperative stimulation parameters may have
important effects on pain; there is also no agreement on how the outcomes of DBS treatment should be
evaluated.27
Non-invasive brain stimulation therapies
A 2014 Cochrane Database Systematic Review28 of randomised controlled trials (RCTs) and quasi-RCTs
of non-invasive brain stimulation techniques for any chronic pain condition identified two small trials
(n = 27 and n = 14) of rTMS that recruited patients with PLP. Our preliminary literature search identified
two further trials of rTMS for PLP: one published in 2016, which was a placebo-controlled double-blind
RCT with 54 participants,29 and one published in 2013, which was a randomised crossover trial with
eight participants.30
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Spinal stimulation therapies
Spinal stimulation therapies include SCS and DRG stimulation therapies. A 2010 literature review of SCS
therapies for PLP31 concluded that for patients in whom medical management has proven inadequate, SCS
is a low-risk intervention that can lead to decreased pain, decreased overall symptomology and improved
functional outcome. A recently published systematic review of SCS for PLP32 identified 12 studies that were
mostly small case series. However, the review reported limited patient, intervention and outcome data,
making interpretation of the study results difficult. DRG stimulation devices have only become available
quite recently.
In summary, studies of stimulation therapies for PLP have not been subject to robust systematic review.
Such a review was therefore warranted to align the evidence base for these therapies with many of the
other treatments for PLP.
Overall aims and objectives of the study
The overall aims and objectives of this study were to determine which types of brain and spinal stimulation
therapy are likely to be the most promising for treating PLP. This was done by undertaking a systematic
review to assess the research evidence on treatment effectiveness and safety. Given the anticipated
limitations of the evidence base, a systematic review of the epidemiology of chronic PLP and a survey of
practising NHS clinicians were also undertaken to help inform future research recommendations.
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Chapter 2 Systematic review
Methods
A systematic review of the clinical literature was undertaken to identify the existing evidence on the
effectiveness and safety of brain and spinal stimulation therapies for PLP. A review of the evidence on the
epidemiology and characteristics of patients with chronic PLP was also undertaken. The review protocol
was registered on PROSPERO (registration number CRD42017065387), an international database of
prospectively registered systematic reviews.
Literature searching
The aim of the literature search was to identify studies of brain and spinal stimulation therapies for PLP
and studies of the epidemiology of PLP.
An information specialist developed the search strategy in MEDLINE (via Ovid). A broad search strategy
was employed based around terms for PLP. To ensure maximal retrieval of relevant studies, the search was
not restricted to brain or spinal stimulation therapies. The MEDLINE strategy was adapted for use in all
resources searched.
The searches were carried out in May 2017. No date, language, geographical or study design limits were applied
to the strategy. The following databases were searched: MEDLINE (including Epub Ahead of Print, In-Process
& Other Non-Indexed Citations, via Ovid MEDLINE Daily and via Ovid MEDLINE), Allied and Complementary
Medicine Database, British Nursing Index, Cochrane Central Register of Controlled Trials, Cochrane Database
of Systematic Reviews, Cumulative Index to Nursing & Allied Health Plus, Database of Abstracts of Reviews of
Effects, EMBASE, Health Technology Assessment database, PsycINFO, PubMed and the Science Citation Index.
In addition, the following resources were searched for ongoing, unpublished or grey literature: PROSPERO,
Conference Proceedings Citation Index: Science, ClinicalTrials.gov, the EU Clinical Trials Register and the
World Health Organization’s International Clinical Trials Registry Platform portal.
The search results were imported into EndNote X8 [Clarivate Analytics (formerly Thomson Reuters),
Philadelphia, PA, USA] and deduplicated. The complete search strategies can be found in Report
Supplementary Material 1.
Supplementary search methods were used to identify intervention studies in broad patient populations
(i.e. those with chronic pain conditions), which may have contained data on patients with PLP. These methods
included forward citation searches and reference checking of key studies and reviews. Clinical experts were
asked about the possibility of any relevant studies or data not picked up using other search methods.
Study selection
Two reviewers independently screened all titles and abstracts obtained through the searches. Full papers of
potentially relevant studies were obtained wherever possible. Two reviewers independently assessed the
relevance of each study using predefined eligibility criteria. Discrepancies were resolved by consensus,
or via a third reviewer when necessary.
The eligibility criteria used to select studies of intervention effectiveness were:
l Population – all patients with PLP resulting from amputation.
l Interventions – DBS, MCS, rTMS, transcranial current stimulation, SCS (also referred to as dorsal column
stimulation) and DRG stimulation. Studies of treatments that combine different types of neurostimulation
therapy were also eligible.
DOI: 10.3310/hta22620 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 62
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
5
l Comparators – any comparator treatment was eligible.
l Outcomes – eligible studies had to report quantitative results for the review’s primary outcome, which
was PLP intensity (either continuous or categorical data).
l Secondary review outcomes included –
¢ frequency and duration of PLP episodes
¢ stump pain
¢ health-related quality of life
¢ level of disability/daily activities
¢ anxiety or depression, if assessed using a validated measure
¢ complications and adverse effects of neurostimulation therapy.
l Study designs – based on the results of the scoping exercise of existing research, only comparative
trials (prospective randomised and quasi-randomised) were eligible for the non-invasive treatments.
Prospective comparative trials and uncontrolled studies were eligible for the invasive therapies. Studies
of heterogeneous cohorts of patients, such as patients with other types of chronic pain, were only
included if results were reported separately for the patients with PLP.
Data extraction and quality assessment
Data extraction forms were piloted and refined as necessary prior to full data extraction. Randomised
trials and quasi-randomised trials were quality assessed using the Cochrane risk-of-bias tool33 and by
consideration of trial external validity. To enhance judgements on selection bias, baseline data were
assessed for group imbalances in PLP intensity, frequency or duration, time since amputation and sizeable
imbalances in the numbers randomised.34
Studies of two or more patients without a control group were quality assessed using the following items
from the PROCESS (preferred reporting of case series in surgery) checklist:35 whether the study was
prospective or retrospective in design, whether participants were consecutively or non-consecutively
recruited and whether the study was single or multicentre. Adequacy of reporting of population and
intervention details was also considered when synthesising results.
Invasive (surgical) interventions were also evaluated based on key aspects of the stages of Innovation,
Development, Exploration, Assessment, and Long-term study (the IDEAL model), as described by the IDEAL
collaboration framework for evidence-based surgery.36
Data extraction and quality assessment were conducted by one reviewer and checked by a second
reviewer for accuracy; any discrepancies were resolved by discussion or via a third reviewer if necessary.
Synthesis
A narrative synthesis was undertaken. Data on key characteristics of patients, interventions and outcomes
were tabulated to provide clear summaries of the included studies. Studies were grouped by design and by
intervention. Differences between studies were discussed in the text, and the potential impact of these
differences on outcomes was explored. Results were interpreted in the context of the results of the study
quality assessments. Pooling of RCTs using meta-analysis was not possible because of heterogeneity of
outcome data.
Review of epidemiology of chronic phantom limb pain
An assessment of the available data on the epidemiology and characteristics of patients with chronic PLP
was undertaken. Survey or registry studies reporting data on the epidemiology and/or characteristics of
patients with chronic, refractory or severe PLP were eligible. To ensure a focus on these patients, studies
had to report data on the level or severity of PLP and include patient inclusion criteria of either ≥ 6 months
since amputation (or start of prosthesis use) or a mean or median time since amputation (or start of
prosthesis use) of ≥ 1 year. In addition, prospective studies that recruited patients prior to amputation were
SYSTEMATIC REVIEW
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eligible if they reported relevant PLP data at or beyond the 6-month time point. To ensure that the number
of included studies would be manageable, cross-sectional studies were only included if they had a sample
of ≥ 100 patients (or 50 patients in studies of bilateral amputees); there were no limits on sample size for
longitudinal studies. The literature searching was conducted as part of that for the review of efficacy and
safety (see Literature searching). Data extraction and synthesis were also as described in Data extraction
and quality assessment and Synthesis.
Results
Quantity and quality of research available
Overall, 11,557 records were retrieved from the searches of the electronic databases and three studies
were identified from other sources (citation searching). Figure 1 shows details of the number of references
excluded at each stage. After removal of duplicates, 6082 titles and abstracts were screened for inclusion.
Of these, 333 records were included based on the title and abstract. The full texts of 303 papers were
assessed against the review eligibility criteria, with 223 excluded at this stage. The full texts of 30 records
were not screened because they were either unobtainable, could not be translated or were identified as
Records screened
(n = 6082)
Records identified
from other sources
(n = 3)
Duplicates removed
(n = 5478)
Included on abstract
(n = 333)
Excluded on abstract
(n = 5749)
• Full text unobtainable,
   n = 17
• Could not translate, n = 10
• Duplicate, n = 3Full text articles screened
(n = 303)
Excluded
(n = 30)
Included
epidemiology
studies
(n = 21, 22 papers)
Included
RCTs
(n = 7, 9 papers)
Included
single group
n ≥ 2
(n = 30, 32 papers)
Included
case reports
(n = 18, 17 papers)
Records identified
through database
searching
(n = 11,557)
Excluded on full text
(n = 223)
• On population, n = 47
• On intervention, n = 8
• On outcome, n = 127
• On study design, n = 35
• Ongoing trials, n = 5,
   6 records
FIGURE 1 Flow diagram of studies through the review.
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duplicates. In total, nine records on seven RCTs, 32 papers on 30 non-comparative group studies, 22 papers
on 21 epidemiology studies and 17 papers on 18 case reports met the eligibility criteria. Of those excluded
based on the full text, 127 were excluded on outcome, 47 on population, 35 on study design and 8 on
intervention. There were also five relevant trials that were still ongoing (i.e. results were not yet available).
Ongoing trials
Details of the five ongoing trials are shown in Table 1. In terms of invasive treatments, there are two
single-group studies of SCS37,38 and a randomised crossover trial of MCS,39 which planned to include
patients with chronic neuropathic pain including PLP. For non-invasive treatments, there is a randomised
crossover trial of transcranial direct current stimulation (tDCS)40 and a RCT of tDCS and mirror therapy,41
which has a factorial design.
Studies of efficacy, effectiveness and safety
Randomised controlled trials
Characteristics of randomised controlled trials
There were nine records reporting on a total of seven separate RCTs that met the inclusion criteria.
Three RCTS were of rTMS,29,43,44 three were of tDCS30,45 and one was of MCS.46 One of the papers on tDCS
described two different RCTs conducted with the same cohort of patients.30 Tables 2 and 3 show baseline
patient characteristics for the included RCTs. Tables 4 and 5 show details of the interventions. The patient
selection criteria used in the RCTs are listed in Report Supplementary Material 2.
TABLE 1 Ongoing trials of neurostimulation that include PLP participants
ClinicalTrials.gov
identifier and title Intervention Study design Participants Location
Status
(November 2017)
NCT02684201; Epidural
Spinal Cord Stimulation for
Sensory Restoration and
Phantom Limb Pain in
Upper-Limb Amputees37
SCS Single-group
study
PLP USA Recruiting participants
NCT03027947; Spinal Root
and Spinal Cord Stimulation
for Restoration of Function
in Lower-Limb Amputees38
SCS Single-group
study
PLP USA Recruiting participants
NCT01554332; Motor
Cortex Stimulation for
Chronic Neuropathic Pain39
MCS Randomised
crossover trial
Chronic
neuropathic pain,
including PLP
Brazil Ongoing but not
recruiting participants
NCT02051959; Long-Term
Treatment of Patients
Experiencing Phantom Limb
Pain With Transcranial
Direct Current Stimulation
(tDCS)40
tDCS Randomised
crossover trial
PLP Israel Suspended participant
recruitment
NCT02487966; Optimizing
Rehabilitation for Phantom
Limb Pain Using Mirror
Therapy and Transcranial
Direct Current Stimulation
(tDCS)41,42
tDCS and
mirror
therapy
RCT with factorial
assignment
PLP USA Recruiting participants
SYSTEMATIC REVIEW
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TABLE 2 Baseline characteristics of participants in the RCTs of non-invasive therapies
Study Country
Interventions
studied
Number
of PLP patients
randomised
Mean age
(years) % male
Unilateral/
bilateral
amputation Amputation site
Amputation
cause
Mean time
since
amputation
(years)
Prosthesis
use (%) Comorbidities
PLP at baseline
(mean VAS
score)
Duration/frequency
of PLP episodes
Ahmed et al. 201143 Egypt rTMS vs. sham 27 52.5 70 Unilateral 60% below knee,
37% above
elbow and 3%
below elbow
22% traumatic,
30% ischaemic
and unclear for
remainder
Unclear mean
‘duration of
illness’ of
2.7 years
NR All participants
had diabetes
mellitus
7.5 NR
Bolognini et al.
201330
Italy tDCS vs. sham 8 59.0 38 Unilateral 62% upper leg,
25% lower leg
and 13% upper
arm
75% blood
vessel disease
and 25%
accident
1.6 63 NR Mean scores
ranged between
2.5 and 3.3 over
the two studies
NR
Bolognini et al.
201545
Italy tDCS vs. sham 8 60.8 75 Unilateral 50% upper leg,
38% lower leg
and 12% upper
arm
63% blood
vessel disease,
25% trauma
and 12%
cancer
4.6 50 NR 5.6 Average frequency
of PLP paroxysms
a
(above background
level): 6.4
Malavera et al.
201629 and 201347,48
Colombia rTMS vs. sham 54 33.9 93 Unilateral Lower limb Landmine 7.8 NR NR 4.9 NR
Irlbacher et al.
200644
Germany rTMS vs. sham 14 46.6 57 Unilateral 50% upper limb NR 15.2 NR NR NR
NR, not reported; VAS, visual analogue scale.
a Scale of 0 (never during the day) to 10 (very frequent).
TABLE 3 Baseline characteristics of participants in the RCT of MCS
Study Country
Interventions
studied
Number of PLP
patients randomised
Mean age
(years) % male Amputation site
Amputation
cause
Mean time since
amputation
(years)
Prosthesis use (%),
comorbidities, PLP at
baseline (mean VAS score)
and duration/frequency
of PLP episodes
Radic et al.
201546,49
Canada MCS, high vs.
low intensity
(subtherapeutic)
stimulation
2a (subgroup of n= 12
with different
neuropathic pain
syndromes)
36.5 100 Second finger in
both patients
NR Mean duration of
pain: 4.9 years
All NR
NR, not reported; VAS, visual analogue scale.
a One patient withdrew because of a protocol breach (stimulator stopped working).
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TABLE 4 Intervention details for the RCTs of non-invasive therapies
Study Intervention Control Location of stimulation Stimulation parameters Notes
Ahmed et al.
201143
rTMS Sham stimulation: coil elevated
and angled away from the head
Optimal scalp position determined
from where transcranial magnetic
stimulation evoked motor potentials
of maximum peak-to-peak amplitude
in muscle proximal to the stump
High frequency: 20 Hz
10-second trains (200 pulses)
every 1 minute
Intensity of stimulation: 80%
of resting motor threshold
10-minute session daily for
5 consecutive days
Bolognini et al.
201330
Trial 1:
l anodal tDCS
Sham stimulation (stimulator
turned off after 30 seconds)
M1
Anodal electrode placed over C3 or
C4 to target hemisphere contralateral
to amputation
Cathode electrode placed over
contralateral supraorbital area
Frequency NR
15-minute sessions
Intensity: 2 mA
Crossover design
Paper reported two trials
undertaken in the same cohort.
One trial targeted the M1,
the other targeted the PPC
Trial 2:
l anodal tDCS
l cathodal
tDCS
Sham stimulation (stimulator
turned off after 30 seconds)
PPC
Hemisphere contralateral to
amputation
Active electrode placed over P3 or P4
Reference electrode placed over
contralateral supraorbital area
Frequency NR
15-minute sessions
Intensity: 2 mA
Bolognini et al.
201545
Anodal tDCS Sham stimulation (current lasted
for 30 seconds)
Motor cortex
Anodal electrode placed over C3 or
C4 to stimulate M1 contralateral to
the amputation
Cathode electrode over the
contralateral supraorbital area
15-minute session
Ramping period of 10 seconds
at beginning and end
Intensity: 1.5 mA
5 consecutive days
Crossover design
SYSTEM
A
TIC
REVIEW
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
10
Study Intervention Control Location of stimulation Stimulation parameters Notes
Malavera et al.
201629 and
201347,48
rTMS Sham stimulation (sham coil) M1 contralateral to the amputated
leg (corresponding to the first dorsal
interosseous muscle of the hand
contralateral to pain)
Frequency: 10 Hz
20-minute sessions – 20 trains of
6 seconds (54-second intertrain
interval)
Intensity of stimulation: 90% of
motor threshold
Daily session for 10 days during
a 2-week period
Irlbacher et al.
200644
rTMS Sham stimulation
Identical placement of coil that
looks and sounds identical and
produces same scalp sensation
but does not activate cortex
M1 area corresponding to affected
phantom limb. Optimal placement
defined by maximal motor response
Frequency: rTMS 1 Hz, 5 Hz
Sham: 2 Hz
1 Hz: ≈8 minutes
2 Hz: ≈4 minutes
5 Hz: ≈1.5 minutes
500 pulses per session
Intensity of stimulation: 95%
of the intensity that evoked
electromyographic response
≥ 0.1 mV in 5 out of 10 trials
when stimulating unaffected
‘mirrored’ M1 area of phantom
limb
Daily session for 5 consecutive
days (see notes)
Three 28-consecutive-day
treatment blocks: 5 days of
baseline metrics, 5 days of
treatment, 5 days of
observation, 18-day wash-out
period, then next block
Not all patients completed the
planned three blocks: six
completed one block, three
completed two blocks and five
completed all three blocks
M1, primary motor cortex; NR, not reported; PPC, posterior parietal cortex.
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Four studies were conducted in Europe,30,44,45 one was conducted in Canada,46 one was conducted in
Egypt43 and one was conducted in Colombia.29 The six RCTs of non-invasive interventions used sham
stimulation as a control. The other RCT46 used high-frequency MCS as the intervention, with low-frequency
stimulation (at a subtherapeutic level) as a placebo treatment. Five of the RCTs had a crossover design,30,44–46
including two crossover trials undertaken on the same cohort but with different targets for tDCS;30 one of
these trials included two active treatments (anodal tDCS and cathodal tDCS) as well as sham stimulation so
patients went through three phases. Similarly, in the crossover trial on rTMS, patients underwent three
different interventions: stimulation at 1 Hz, 5 Hz and sham stimulation.44 The two trials reported in Bolognini
et al.30 differed in design from the other RCTs of non-invasive treatments as patients underwent just one
session of each intervention, separated by ≥ 3 hours, with outcome assessments made immediately and
after 90 minutes. The other non-invasive trials involved daily sessions for a period of 5–10 days and longer
follow-up periods (except for one44 in which measurements were taken 15 minutes after the intervention).
Some trials included patients with chronic pain conditions other than PLP, but data were only extracted on
PLP patients. The RCT of MCS46 included only two patients with PLP, one of whom withdrew from the
study. Sample sizes of PLP patients in the RCTs of non-invasive treatments varied, ranging from 8 to
54 participants. Participant mean ages ranged from 33.9 to 60.8 years. Over 70% of patients were male
in all but one study,30 in which 38% were male.
All the RCTs included only patients with unilateral amputations. Five of the studies included patients with
upper or lower-limb amputations,30,43–45 whereas one included only lower-limb amputees.29 Both of the
patients in the RCT of MCS46 had finger amputations. Causes of amputation varied and were not reported
in two trials.44,46 One RCT specifically included only landmine victims.29 In the remaining four RCTs,30,43,45
22% to 25% of amputations resulted from trauma or accident. Blood vessel disease accounted for the
majority of amputations in three of these trials.30,45 The mean time since amputation was reported in five
trials29,30,44,45 and ranged from 1.6 to 15.2 years. The other trials reported a mean duration of pain of
4.9 years46 and a mean duration of illness of 2.7 years, respectively,43 although it was not clear in the latter
study whether illness referred to PLP or diabetes mellitus (which all participants had).
TABLE 5 Intervention details for the RCT of MCS
Study Intervention Control Surgical methods Location of stimulation Stimulation parameters
Radic et al.
201546,49
High-intensity
MCS
Low-intensity
MCS
(subtherapeutic)
A four-contact
electrode was placed
in epidural space
through burr hole
No mention of trial
period
Contralateral motor
cortex
Electrode aligned parallel
or perpendicular to
the central sulcus.
Intraoperative stimulation
used to check location
Stimulation applied in
cycling mode. High
intensity: on for 10 minutes,
off for 2 hours. Low
intensity on for 1 minute,
off for 6 hours
Amplitude and pulse
width set to 70% motor
threshold
Motor threshold: 3.9,
amplitude 2.7 V, pulse
width 450 microseconds in
one patient
Motor threshold: 4,
amplitude 2.8 V, pulse
width 210 microseconds in
other patient
Frequency: 50 Hz
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Baseline PLP intensity ranged from 4.9 to 7.5 on a visual analogue scale (VAS) (scale of 0–10) in the three
trials that reported it.29,43,45 One publication reported the mean VAS score before tDCS in each of two
different trials on the same patients, which was much lower than the other studies, ranging from 2.5 to
3.3.30 One trial reported the average frequency of PLP episodes above the background level as 6.4 on a
0–10 scale (0 = never during the day, 10 = very frequent),45 but neither mean duration nor frequency of
PLP episodes at baseline were reported in any other trial.
Trial risk-of-bias assessment results
The results of the risk-of-bias assessments are presented in Table 6. The Bolognini et al.30 paper had results
for two distinct but closely related trials; for the purposes of this risk-of-bias assessment, these two trials
were sufficiently similar to record the results as one trial. Three of the five trials that were assessed for risk
of bias had a crossover design, in which patients acted as their own controls,30,44,45 and two trials had a
parallel-group design.29,43
One trial43 had a high-risk judgement for overall risk of bias owing to the use of quasi-randomisation:
patients were allocated treatments on the basis of the day of the week. This may be the reason for the large
imbalance in patient numbers across treatment groups seen in this trial (17 were allocated to the active
treatment group and 10 were allocated to the sham group). One trial45 had an unclear risk judgement for
overall risk of bias because of the lack of detail on whether or not the trial had missing data (i.e. it was
unclear whether or not patients dropped out of the trial and how any such missing data were handled in
the analyses). This trial was a crossover trial and the risk of selection bias was likely to be low; it reported
that the same number of participants were randomised to the two intervention sequences, which would
eliminate the impact of any period effects (i.e. differences between responses in the second period
compared with responses in the first period that were not caused by the interventions being trialled).45
The remaining three trials29,30,44 had low risk judgements for overall risk of bias. Although the randomisation
method details were not well reported for two of these trials,30,44 their crossover designs meant that the
risk of selection bias was likely to be low; in one trial,30 there was no follow-up (i.e. assessments were
immediately after treatment) and the gap between interventions was very short, ruling out the possibility of
period effects. Both trials30,44 reported the use of designs that would minimise carry-over effects between
treatments: one30 stated that the different treatment sessions were separated by > 3 hours, during which
time PLP had returned to baseline, and one44 reported the use of 18-day wash-out phases.
Randomised controlled trial results for non-invasive treatments
Results from the randomised and quasi-randomised trials of non-invasive treatments (tDCS and rTMS) are
presented in Table 7.
Transcranial direct current stimulation Two publications – both by Bolognini et al.30,45 – reported on
trials of the efficacy and safety of tDCS for PLP. Bolognini et al.30 studied the immediate effects of two
variants of tDCS in the same cohort of patients: tDCS to the primary motor cortex (M1) and tDCS to the
posterior parietal cortex (PPC). This study found a significant but very short-term benefit (of < 90 seconds)
of tDCS to M1 on the pain of PLP but no benefit on pain from tDCS to the PPC. The other Bolognini
et al.45 publication reported on a trial of the effects of 1 week of treatment with tDCS in M1 and found a
significant benefit at the end of treatment, with the benefit sustained for a further week of (no treatment)
follow-up. The Bolognini et al.45 trial also evaluated depression as an outcome, reporting a statistically
significant effect favouring tDCS. Baseline data identified the trial population as being mostly comprised of
patients with mild depression.45 No significant differences were reported for stump pain in the Bolognini
et al.45 trial. Clearly, these trials are limited by their small sample sizes and short follow-up periods.
Moreover, the baseline data suggest that the trial results should only be viewed as being applicable to
patients with quite mild PLP.
Across all the tDCS trials, there was little difference between active tDCS and sham in terms of the summary
scores of the specific types of adverse effects that were evaluated.
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TABLE 6 Results of randomised and quasi-randomised trial risk-of-bias assessments
Study
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of participants and
researchers
Blinding of outcome
assessment
Incomplete outcome
data Selective reporting
Overall
judgement
Ahmed et al. 201143
Judgement High risk High risk High risk Low risk Low risk Unclear risk Low risk High risk
Support Allocation on the basis of day of the
week
Large imbalance in
group numbers: 17 in
intervention vs. 10 in
sham
Patients blinded. Researcher
giving treatment not blinded but
clinic time only 10 minutes
Patient self-assessment.
Realistic sham stimulation
No CONSORT diagram or
description of patient flow
through trial
Relevant pain
outcomes reported
Bolognini et al. 201330
Judgement Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Support No details other than ‘randomised’ but
this was a crossover trial. Treatment
sessions were short, as were the gaps
between treatments. The follow-up
time point was immediately after the
intervention, so minimal risk of period
effects
Patients acted as their
own control (crossover
study)
Patients blinded. Sham stimulator
turned off after 30 seconds
Assessments were either
immediately after or 90 minutes
after treatment
Blinded patient self-assessment.
Validation reference cited in
paper
Number randomised not
totally clear but attrition
very unlikely owing to very
short follow-up
Review-relevant
outcomes reported
Methods also
suggested low
risk of carryover
effects
Bolognini et al. 201545
Judgement Low risk Low risk Low risk Low risk Low risk Unclear risk Low risk Unclear risk
Support Few randomisation details. But this was
a crossover trial and the same number
of participants were randomised to the
two intervention sequences (i.e. active
then sham, and sham then active).
This would eliminate the impact of any
period effects
Crossover design Patients blinded. Sham stimulator
turned off after 30 seconds.
Sessions were short so unlikely to
be differences in cointerventions
from carers
Blinded patient self-assessment.
Validation reference cited in
paper
No details provided Review-relevant
outcomes reported
Based primarily
on lack of detail
on patient flow
through trial
Irlbacher et al. 200644
Judgement Low risk (probably) Low risk (probably) Low risk Low risk Low risk Low risk Low risk Low risk
Support No details other than ‘randomised’ but
crossover design used so likely to be
low risk
Crossover design Participants blinded. Sham device
realistic. Caregivers not blinded
but sessions were short so
unlikely to be differences in
cointerventions from carers
All outcomes were patient
self-assessed and patients were
blinded
Dropouts evenly distributed
across groups: n= 9 for all
three treatment groups.
14 patients were recruited
No protocol, but no
obvious discrepancy
or omission or logical
non-consistency
between design and
reported outcomes
18-day wash-out
phase between
treatments
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Study
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of participants and
researchers
Blinding of outcome
assessment
Incomplete outcome
data Selective reporting
Overall
judgement
Malavera et al. 201629
Judgement Low risk Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk
Support A computer-generated randomisation
method with a permuted block size of
six was used. The randomisation code
was only given to the treating
investigator on the first day of
treatment session by an independent
investigator not involved with any other
aspect of the trial
Frequency and
duration of PLP not
reported
Patients blinded. Sessions
were short so unlikely to be
differences in cointerventions
from carers
Patient self-assessment. When
asked, patients were not able
to tell which treatment they
were on
Low risk for 15-day results.
Six patients with missing
data at day 30 – some
uncertainty whether or not
imputation methods were
appropriate
Review-relevant
(primary) outcome
reported as stated on
trial registry
CONSORT, Consolidated Standards of Reporting Trials.
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TABLE 7 Randomised and quasi-randomised trial results of non-invasive brain stimulation therapies for PLP
Study Outcome measure Resultsa
Trials of tDCS
Bolognini et al. 201330
(trial 1, n= 8 crossover;
tDCS in M1)
PLP: VAS 0–10 p-values for this study are for comparisons
between follow-up time point and
baseline; the follow-up time point was
immediately after the intervention
Anodal tDCS of M1: baseline 2.6 vs. post
tDCS 0.8; p< 0.02
Sham: baseline 3.3 vs. post tDCS 2.6;
p= 0.3
PLP returned to near-baseline levels after
90 minutes
Stump pain VAS No significant effect reported for stump
pain (p= 0.8). Results presented only as a
graph
Adverse effects: 0–27 scoreb tDCS of M1 2.6, sham 2.1; p= 0.36
Bolognini et al. 201330
(trial 2, n= 7 crossover;
tDCS in PPC)
PLP: VAS 0–10 No significant differences, ANOVA p= 0.7.
Results presented only as a graph
Stump pain VAS No significant differences, ANOVA p= 0.1.
Results presented only as a graph
Adverse effects: 0–27 scoreb tDCS 2.43, sham 2.13; p= 0.45
Bolognini et al. 201545
(crossover, n= 8;
tDCS in M1)
PLP: VAS 0–10, % change from baseline ANOVA showed significant effect of the
tDCS week (sham or active); p= 0.04
tDCS –28%, sham –9%; p = 0.04
Difference compared with sham week:
immediately after 1 week of active tDCS
–42%; p= 0.04. Follow-up week (i.e.
1 week following active/sham weeks)
–41%; p= 0.04
PLP: frequency of paroxysms (0–10 VAS),
% change from baseline
Main effect of week showed a significant
reduction during the week of active tDCS
–33%; p= 0.03
Significant reduction during follow-up
week –44%; p = 0.01. Sham week –9%
Beck Depression Inventory Prior to tDCS, 14; after final tDCS
(and sham), 11; p= 0.05
Adverse effects: 0–27 scoreb tDCS, 3.22; sham, 2.74; p= 0.31
No adverse effects reported
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TABLE 7 Randomised and quasi-randomised trial results of non-invasive brain stimulation therapies for PLP
(continued )
Study Outcome measure Resultsa
Trials of rTMS
Ahmed et al. 201143
(rTMS, n= 17; sham,
n= 10)
PLP: VAS 0–10 p-values for this study are for comparisons
between follow-up time point and baseline
Baseline:
l rTMS, 7.4 (1.3)
l sham, 7.6 (0.84)
After one session:
l rTMS, 7.1 (2.1); p= 0.40
l sham, 7.80 (0.91); p= 0.59
After five sessions:
l rTMS, 3.4 (1.2); p= 0.001
l sham, 7.40 (0.84); p= 0.59
1 month (from final session):
l rTMS, 3.4 (1.7); p= 0.001
l sham, 7.3 (0.8); p= 0.46
2 months (from final session):
l rTMS, 4.5 (2.2); p= 0.001
l sham, 7.6 (1.0); p= 1.0
Pain: Leeds assessment of neuropathic
symptoms and signs
Baseline:
l rTMS, 17.2 (3.7)
l sham, 18.10 (1.9)
After one session:
l rTMS, 16.8 (3.4); p= 0.38
l sham, 17.30 (1.9); p= 0.11
After five sessions:
l rTMS, 8.4 (3.7); p= 0.001
l sham, 17.8 (2.3); p = 0.49
1 month (from final session):
l rTMS: 7.6 (2.7); p= 0.001
l sham: 17.4 (2.2); p = 0.19
2 months (from final session):
l rTMS: 9.5 (3.7); p= 0.001
l sham: 16.8 (1.7); p = 0.04
continued
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TABLE 7 Randomised and quasi-randomised trial results of non-invasive brain stimulation therapies for PLP
(continued )
Study Outcome measure Resultsa
Hamilton Rating Scale for Depression score rTMS:
l before 19.5 (6.7), after 10.4 (4.6);
p= 0.0001. Follow-up time point was
not specified
Sham:
l before 17.1 (1.6), after 15.4 (2.4);
p= 0.07
Hamilton Anxiety Rating Scale score rTMS:
l before 15.8 (3.4), after 9.6 (2.9);
p= 0.0001. Follow-up time point was
not specified
Sham:
l before 15.8 (1.7), after 16.2 (1.5);
p= 0.39
Malavera et al. 201629
and 201347,48 (rTMS,
n= 27; sham, n= 27)
PLP: number with ≥ 30% reduction in VAS score
compared with baseline; primary outcome
15 days (after end of treatment): rTMS 19
(70.3%) vs. sham 11 (40.7%), RR= 1.72,
95% CI 1.03 to 2.89
30 days: rTMS 15 (55.5%) vs. sham 9
(33.3%), RR = 1.66, 95% CI 0.88 to 3.13
PLP: absolute VAS scores Baseline: rTMS 4.98 (1.97), sham 4.82
(1.98)
15 days: rTMS 2.3 (2.5), sham 3.7 (3.0).
Mean between group difference = 1.4,
95% CI –0.07 to 2.93; p= 0.06
30 days: rTMS 3.0 (2.6), sham 3.9 (2.7).
Mean between group difference = 0.9,
95% CI –0.59 to 2.31; p= 0.24
Zung self-rating depression scale Baseline: rTMS 26.7 (5.7), sham 25.6 (6.8)
15 days: rTMS 25.1 (5.9), sham 24.2 (4.4)
30 days: rTMS 24.9 (9.1), sham 23.2 (3.0)
No statistically significant between-group
differences
Zung self-rating anxiety scale Baseline: rTMS 27.8 (7.7), sham 26.9 (9.3)
15 days: rTMS 25.8 (7.0), sham 25.1 (5.5)
30 days: rTMS 23.8 (7.3), sham 24.4 (4.2)
No statistically significant between-group
differences
Adverse effects No significant differences between groups
in minor adverse effects, such as headache,
neck pain and sleepiness. No serious
adverse effects were reported
SYSTEMATIC REVIEW
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Repetitive transcranial magnetic stimulation Three trials compared rTMS with sham rTMS.29,43,44
The largest trial,29 which randomised 54 participants with PLP, was rated as having a low overall risk of
bias. Results for the trial’s primary outcome – the number of patients with a ≥ 30% PLP reduction from
baseline, at 2 weeks after the end of treatment – demonstrated a statistically significant difference
favouring rTMS over sham. However, the result was not statistically significantly different at 1 month after
the end of treatment, and no statistically significant between-group differences were seen at either of
these time points when absolute PLP VAS data were used in the analyses. No statistically significant
between-group differences were seen for the trial’s anxiety, depression and adverse effects outcomes.
A small, quasi-randomised trial43 reported statistically significant improvements in PLP directly after five
rTMS sessions and at both 1 month and 2 months after the final session. This trial also reported statistically
significant improvements in depression and anxiety, although the relevant follow-up time points for these
results were not stated. However, this trial reported its analyses as comparisons between follow-up time
points and baseline for each intervention (rTMS and sham), rather than as comparisons between the
intervention groups. More importantly, this trial’s results were judged to be at a high risk of bias and,
therefore, they should not be considered as reliable estimates of effect.
The third trial was a small study of 5 days of treatment reported by Irlbacher et al.44 It found similar PLP
reductions immediately after stimulation across groups, including sham stimulation. It was judged to have
a low risk of bias, but the sample size was small (only 14 patients). The authors concluded that, at present,
rTMS should not be recommended as a standard therapy for PLP.
Two of the three rTMS trials29,43 reported data on PLP intensity 1 month after the end of treatment. The
two results are presented in a forest plot (Figure 2), although they were too different to justify pooling.
The result from the trial that was rated as having a low risk of bias, reported by Malavera et al.,29 shows no
statistically significant difference between rTMS and sham, whereas the result from the quasi-randomised
trial reported by Ahmed et al.,43 which has been rated as having a high risk of bias, shows quite a large and
statistically significant effect favouring rTMS.
TABLE 7 Randomised and quasi-randomised trial results of non-invasive brain stimulation therapies for PLP
(continued )
Study Outcome measure Resultsa
Irlbacher et al. 200644
(n = 14 crossover; rTMS)
PLP: VAS 0–100
Pre and post scores are separately averaged over
five measurements (daily measurements taken
over 5 consecutive treatment-days)
Immediately before treatment (mean, over
5 days):
l rTMS 1 Hz, 43.8 (29.3)
l rTMS 5 Hz, 53.0 (25.5)
l sham 2 Hz, 45.9 (28.7)
15 minutes after treatment (mean, over
5 days), n= 9:
l rTMS 1 Hz, 42.2 (27.9)
l rTMS 5 Hz, 49.9 (23.3)
l sham 2 Hz, 43.7 (29.7)
ANOVA, analysis of variance; CI, confidence interval; M1, primary motor cortex; PPC, posterior parietal cortex; RR, risk ratio;
SD, standard deviation.
a Mean (SD) unless otherwise stated.
b Calculated as the sum of intensity rating (0–3) for nine separate items (headache, neck pain, scalp pain, scalp burn,
prickle, reddened skin, drowsiness, difficult concentration and mood changes).
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– 10 – 5 0
Mean difference
IV, random, 95% CI
Mean difference
IV, random, 95% CIWeightTotalSDStudy
Ahmed et al. 201143
Malavera et al. 201629
3.4
3.0
1.7
2.6
17
27
7.3
3.9
0.8
2.7
10
27
– 3.90 (– 4.85 to – 2.95)
– 0.90 (– 2.31 to 0.51)
Mean TotalSD
rTMS Sham rTMS
Mean
5 10
Favours rTMS Favours sham rTMS
FIGURE 2 Forest plot of rTMS trial results for PLP intensity (VAS 0–10 scores) 1 month after the end of treatment. CI, confidence interval; IV, instrumental variable;
SD, standard deviation.
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Results for invasive treatments
Although one randomised trial46 was identified that recruited patients with PLP, it provided outcome data
for only a single PLP patient and so cannot be evaluated as a RCT in the present context. This study was of
MCS and recruited patients with a range of different neuropathic pain conditions. Only two patients had
PLP, both with phantom finger pain. After recruiting 12 patients, the trial was stopped early owing to a
lack of efficacy. One PLP patient was among the six patients who completed the trial: for this patient, the
stimulator was explanted owing to a lack of benefit at 33 months (Table 8). Six patients withdrew early
from the trial.
Summary
Results from a good-quality randomised trial29 of 54 PLP patients suggest worthwhile benefits of rTMS in
reducing PLP, but not in reducing anxiety or depression. However, the PLP benefit seen at 2 weeks after
the end of treatment was no longer evident at 4 weeks after the end of treatment. Small randomised
trials30,45 of tDCS to M1 suggest the possibility of modest, short-term reductions in PLP. Although both
interventions appear safe, larger trials with longer follow-up periods would be needed to resolve the
considerable uncertainty about the true potential of these non-invasive treatments for PLP. There is no
RCT evidence available for invasive neurostimulation treatments for PLP.
TABLE 8 The RCT results for invasive treatments
Study Outcome measure Resultsa
Radic et al. 201546,49 (MCS; n= 2 with PLP,
crossover trial; one PLP patient withdrew)
PLP VAS % change At 12 weeks’ follow-up, with high-intensity
stimulation compared with low-intensity
stimulation, there was no change in VAS score
during activities or the ‘most pain’ VAS score.
There was a reduction in VAS score during rest
of around 23% and a reduction in the ‘least
pain’ of around 17%
McGill Pain Questionnaire
absolute scores
Small decrease (< 5) from baseline in total
score for low-intensity stimulation. No change
for high-intensity stimulation
Increase from baseline in miscellaneous score
for low- (1-point increase) and high-intensity
stimulation (2-point increase)
SF-36 With high-intensity stimulation compared with
low-intensity stimulation, there was around a
15% reduction in the mental summary score,
and no change in the physical summary score
BDI II Small increase from baseline in BDI score for
low- (around 5 points) and high-intensity
stimulation (around 2 points)
Standard 7-point Patient
Global Impression of
Change
No difference between low- and high-intensity
stimulation: Patient Global Impression of
Change score of 4
Long-term follow-up At 33 months’ follow-up, the stimulator was
explanted because of the lack of benefit
Adverse events The PLP patient who withdrew did so because
their stimulator turned off unexpectedly
BDI, Beck Depression Inventory; SF-36, Short Form questionnaire – 36 items.
a For the PLP patient, data are presented only in graphs.
Note
Follow-up time points of 12 weeks for both the intervention and the control.
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Non-comparative group studies
Characteristics of non-comparative group studies
Thirty non-comparative group studies, which were mostly case series, met the inclusion criteria. Nine studies
were of DBS,50–58 four were of MCS,59–62 three were of DRG stimulation63–65 and 14 were of SCS.66–78
Some study cohorts overlapped. Five patients treated with DBS in a single-centre case series51 were all
included in a cohort of 14 patients treated at two centres reported in another publication.52 The five
patients were also included in a further paper with 3-year follow-up results, with the addition of one
patient to the cohort.58 One study of SCS76 probably includes results for patients already reported in an
earlier paper,77 but not enough information was available to be sure these are all the same patients.
Five studies were reported only as conference abstracts.52,53,63,65,72 Tables 9–11 outline the basic design
characteristics of the non-comparative group studies; many papers did not report adequate details.
Of those that reported design methods, seven were prospective50–52,54,58,61,63 and eight were retrospective
studies.59,64–66,71,72,75 Fifteen studies were conducted at a single centre50,51,54,58,61,62,65,68,69,73–77 and three
reported data from multiple centres.52,66,79 Patient recruitment was reported as being consecutive in
nine studies.50–52,58,59,64,65,69,75
Tables 12–14 present the baseline characteristics of patients included in the non-comparative group studies.
The number of patients with PLP ranged from 2 to 26, with most studies including fewer than 10 PLP
patients. Baseline characteristics for the subgroups of patients with PLP were not available in many of the
publications that reported on mixed cohorts of chronic pain patients. When reported, the mean age of
patients with PLP ranged from 38.8 to 74.7 years. In most studies, most patients were male.
The site of amputation varied: in 10 papers,50,51,56,59,62,64,68,73,78 all or most patients had lower-limb amputation;
in four papers57,60,61,70 all or most had upper-limb amputations; and there were equal numbers in two
papers.58,65 In seven of the studies that reported cause of amputation,51,52,56,58,70,71,78 all or most patients had
undergone amputation because of trauma. Three studies67,68 only included patients who had undergone
amputation as a result of disease (including cancer) and the remainder had mixed causes or the cause
was unreported.
Few studies reported the mean time since amputation, although some reported the duration of pain.
The mean duration of pain patients had experienced prior to the intervention ranged from 2.6 to 23.0 years.
Baseline intensity of PLP was not reported in most studies and different measurements were used in the few
studies that did report it. In those studies that reported PLP on a VAS, mean scores were > 7 (on a VAS of
TABLE 9 Motor cortex stimulation: key design characteristics of non-comparative group studies
Study Design characteristics
Carroll et al. 200061 Prospective, single-centre audit of neuropathic pain cases (1995–8)
NR whether consecutive or non-consecutive
Hosomi et al. 200859 Retrospective, consecutive case series of neuropathic pain patients
NR whether single or multicentre
Saitoh et al. 200062 Single-centre case series of deafferentation pain patients (1996–8)
Unclear whether consecutive or non-consecutive
NR whether retrospective or prospective
Sol et al. 200160 Details NR
NR, not reported.
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TABLE 10 Deep brain stimulation: key design characteristics of non-comparative group studies
Study Design characteristics
Abreu et al. 201758 (same cohort as Pereira
et al. 2013,51 with one additional patient)
Prospective, single-centre, consecutive case series of patients with chronic
neuropathic pain after amputation or BPA (2009–12)
Bittar et al. 200556 Case series; method details NR
Boccard et al. 201350 Prospective, single-centre, consecutive case series of chronic neuropathic
pain patients over 12 years (1999–2011)
Chamadoira et al. 201153 (conference
abstract)
Case series; NR whether prospective or retrospective, single or multicentre,
or consecutive or non-consecutive recruitment
Mundinger and Salomão 198057 Study of chronic pain patients
NR whether single or multicentre, or consecutive or non-consecutive
recruitment
Unclear whether retrospective or prospective
Owen et al. 200754 Prospective, single-centre study of neuropathic pain patients
NR whether consecutive or non-consecutive recruitment
Pereira et al. 201252 (conference abstract) Prospective study of consecutive patients treated in two European centres
(2003–11)
Pereira et al. 201351 (from same cohort as
Pereira et al. 201252)
Prospective, single-centre, consecutive case series of patients with chronic
neuropathic pain after amputation or BPA (2009–11)
Yamamoto et al. 200655 Method details NR
BPA, brachial plexus avulsion; NR, not reported.
TABLE 11 Spinal stimulation therapies: key design characteristics of non-comparative group studies
Study Design characteristics
Dorsal root ganglion stimulation
Eldabe et al. 201564,79 Retrospective review of records of all patients receiving DRG stimulation at
multiple European sites
Love-Jones et al.63 (conference abstract) Prospective series of patients with PLP and/or stump pain enrolled in five
clinical trials
Wahlstedt and Leljevahl 201365 (conference
abstract)
Retrospective, single-centre, consecutive case series
Spinal cord stimulation
Broggi et al. 199466 Retrospective, multicentre study of chronic pain patients in 23 Italian centres
NR whether consecutive or non-consecutive recruitment
Claeys and Horsch 199767 Case series (1986–92)
Method details NR
De Caridi et al. 201668 Multiple case report from a single centre
NR whether retrospective or prospective, or consecutive or non-consecutive
recruitment
Patients with both PLP and lower-limb ischaemia
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TABLE 11 Spinal stimulation therapies: key design characteristics of non-comparative group studies (continued )
Study Design characteristics
Devulder et al. 199069 Review of consecutive patients in a single centre
NR whether prospective or retrospective
Garcia-March et al. 198770 Study of BPA patients; method details NR
Katayama et al. 200171 SCS, DBS and MCS
Retrospective review of patients
NR whether single centre or multicentre, or consecutive or non-consecutive
recruitment
Eligibility criteria allowed patients with pain in a non-existing limb regardless
of whether the original limb had been amputated or not; 11 of 19 patients
had BPA; most of these had undergone arm amputation but some had not
so only data for the eight non-BPA patients are extracted here
Krainick et al. 197578 Method details NR
Miles et al. 197477 Single-centre study
NR whether retrospective or prospective, or consecutive or non-consecutive
recruitment
Miles and Lipton 197876 Single-centre case series
Unclear whether retrospective or prospective, or consecutive or
non-consecutive
Naidu et al. 201372 (conference abstract) Retrospective review of clinical records (2010–12)
NR whether single centre or multicentre, or consecutive or non-consecutive
recruitment
Cases included that used specific method for spinal target selection
Nittner 198273 Single-centre study; NR whether retrospective or prospective, or consecutive
or non-consecutive recruitment
Sánchez-Ledesma et al. 198974 Single-centre case series of deafferentation pain patients
Unclear whether retrospective or prospective, or consecutive or
non-consecutive recruitment
Viswanathan et al. 201031 Retrospective review of prospectively collected data (patient records) at
single centre (2003–8)
Unclear whether consecutive or non-consecutive recruitment
Wester 198775 Retrospective, single-centre, consecutive study of chronic pain patients
(1978–84)
BPA, brachial plexus avulsion; NR, not reported.
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TABLE 12 Motor cortex stimulation: baseline characteristics of non-comparative group studies
Study
Number with
Mean age (years) Sex
Amputation sites
and causes Time since amputation Baseline PLP
Duration/frequency
of PLPPLP Stump paina
Carroll et al.
200061
3 1 47.7 Two males,
one female
Two upper limb,
one lower limb
Mean of approximately 15 years
of pain duration (range 5–22 years)
(estimate based on year of pain
onset and year of intervention)
NR Constant pain in all
patients
Causes NR
Hosomi et al.
200859
4 1 58.5 Four males All lower limb
(one bilateral)
Mean of 5.5 years of pain duration NR NR
Causes NR
Saitoh et al.
200062
2 1 57.5 Two males Both lower limb NR VAS score of 10
in both patients
NR
Sol et al. 200160 3 NR Individual ages and
mean NR
Range 44–52
Three males All upper limb Mean of 11 years of pain duration
(range 2–27 years)
NR Constant pain in all
patients
Causes NR
NR, not reported.
a In addition to PLP.
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TABLE 13 Deep brain stimulation: baseline characteristics of non-comparative group studies
Study
Number with Mean
age
(years) Sex Amputation sites and causes
Time since
amputation Baseline PLP
Duration/
frequency
of PLPPLP Stump paina
Abreu et al. 201758 (same
cohort as Pereira et al. 2013,51
with one additional patient)
6 NR 55.7 Four males,
two females
Three above elbow, two above
knee, one below knee
All trauma
Mean 23.0 years
of pain duration
Median VAS score: 6
Median UWNPS: 63
Median BPI score: 11.5
NR
Bittar et al. 200556 3 NR 55.7 Three males Two lower limb, one upper limb
Two trauma, one vascular
insufficiency
NR NR NR
Boccard et al. 201350 9 NR (some had
stump pain)
51.8 Seven males,
one female
One upper limb, eight lower limb,
including one bilateral lower limb
Causes NR
NR NR NR
Chamadoira et al. 201153
(conference abstract)
4 NR NR NR NR NR NR NR
Mundinger and Salomão
198057
7 4 47.9 Seven males Four upper limb (one above elbow,
one below elbow, two not
specified), three lower limb
(two above knee, one not specified)
Causes NR
NR NR NR
Owen et al. 200754 7 NR NR NR NR NR NR NR
Pereira et al. 201252
(conference abstract)
14 NR 52 11 males,
three females
Amputation site NR (one bilateral) NR NR NR
11 trauma, three ischaemia,
one infection
Pereira et al. 201351 (from
same cohort as Pereira et al.
201252)
5 NR 54.2 Three males,
two females
Two above knee, two above elbow,
one below knee
All trauma
Mean 19.6 years
of pain duration
Mean VAS score: 7.0 (SD 2.8) NR
Mean UWNPS: 72.2 (SD 17.3)
Mean BPI score 13.6 (SD 3.8)
Yamamoto et al. 200655 11 NR NR NR NR NR NR NR
BPI, Brief Pain Inventory; NR, not reported (for PLP subgroup); SD, standard deviation; UWNPS, Median University of Washington Neuropathic Pain Score.
a In addition to PLP.
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TABLE 14 Spinal stimulation therapies: baseline characteristics of non-comparative group studies
Study
Number with
Mean age
(years) Sex
Amputation sites
and causes Time since amputation Baseline PLP
Duration/
frequency
of PLPPLP Stump paina
Dorsal root ganglion stimulation
Eldabe et al. 201564,79 8 3 52.2 (based
on n = 5 only)
Five females,
two males,
one NR
Four leg, two arm,
two foot; wide variation
in causes
Mean 7.9 years, n= 7+ 1
NR (range 1 to 18 years)
Mean VAS score 83.5
(SD 10.5)
NR
Love-Jones et al.63
(conference abstract)
NR but 22 with PLP
and/or stump pain
NR NR NR NR Mean VAS score 86.1
(SD 10.5, n= 14).
Includes some patients
with only stump pain
NR
Wahlstedt and Leljevahl 201365
(conference abstract)
2 2 NR NR One hand, one foot NR NR NR
Spinal cord stimulation
Broggi et al. 199466 26 NR NR NR NR NR NR NR
Claeys and Horsch 199767 7 NR 64.1 Five males,
two females
Amputation site NR
All chronic limb
ischaemia
Mean 2.6 years
(SD 0.6 years) pain
duration
NR NR
De Caridi et al. 201668 3 0 74.7 Two males,
one female
All lower limb
All peripheral arterial
disease
Two patients: ≈6 months
One patient: < 4 months
VAS score of > 90 in
one patient
NR in two patients
NR
Devulder et al. 199069 5 NR NR NR NR NR NR NR
Garcia-March et al. 198770 2 2 40.5 Two males All upper limb
All brachial plexus
avulsion (owing to
trauma)
Mean 15.5 months of
pain duration
NR NR
Katayama et al. 200171 8 NR NR NR Amputation site NR
All trauma, neoplasms
or infections
NR NR NR
continued
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TABLE 14 Spinal stimulation therapies: baseline characteristics of non-comparative group studies (continued )
Study
Number with
Mean age
(years) Sex
Amputation sites
and causes Time since amputation Baseline PLP
Duration/
frequency
of PLPPLP Stump paina
Krainick et al. 197578 4b 1 NR NR Three above knee,
one above elbow
Three trauma,
one vascular
NR NR NR
Miles et al. 197477 5 NR 43.8 Four males,
one female
NR Mean 18.1 years of pain
duration
NR NR
Miles and Lipton 197876 9 NR NR NR NR (minimum of two
upper limb)
NR NR NR
Naidu et al. 201372
(conference abstract)
5 NR NR NR NR NR VAS scores of > 7.5 in
all patients
NR
Nittner 198273 7 (unclear
if all had
amputation)
3 57.4 Six males,
one female
All lower limb
Causes not clear
NR NR NR
Sanchez-Ledesma et al. 198974 6 NR NR NR NR NR NR NR
Viswanathan et al. 201031 4 NR 38.8 Three males,
one female
Two above knee,
one hip disarticulation,
one hemisacrectomy
All cancer
One patient: ≥ 30 years
Three patients: < 7 years
NR NR
Wester 198775 5 NR NR NR NR NR 1–3 scale (3 = strong
pain, 2=moderate
pain, 1=weak pain);
average of 2.50 (n= 4)
NR, not reported (for PLP patients); SD, standard deviation.
a In addition to PLP.
b Included 52 patients with PLP or stump pain but data were only reported separately for four PLP patients.
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1–10) or > 70 (on a VAS of 0–100) in all cases, except in one study that reported a median score of 6.58
Only two studies60,61 reported any information on the duration or frequency of PLP episodes, both specifying
that pain was constant in all patients.
Results of non-comparative group studies
Motor cortex stimulation All four of the included MCS studies were small, each reporting on four or
fewer patients. Across all four studies, 12 patients were studied in total. The quality assessment results are
presented in Table 15. One study was prospective,61 one was retrospective59 and the method of recruitment
was unclear in two studies.60,62 One study59 reported that consecutive patient data were used and three
studies60–62 did not clearly report how patients were selected. Two studies61,62 were based on experience at a
single centre but these details were not reported in the other studies.59,60 In terms of the IDEAL stages, MCS
research has not progressed beyond the development/exploration stage. In two studies,60,61 all the patients
had constant PLP before intervention with MCS.
TABLE 15 Quality assessment results for the non-comparative group studies
Study IDEAL stagea
Prospective or
retrospective design
Single
centre/multicentre Recruitment
Motor cortex stimulation
Carroll et al. 200061 2a Prospective Single NR
Hosomi et al. 200859 2a Retrospective NR Consecutive
Saitoh et al. 200062 2a NR Single NR
Sol et al. 200160 1/2a NR NR NR
Deep brain stimulation
Abreu et al. 201758 2b/3 Prospective Single Consecutive
Bittar et al. 200556 1/2a NR NR NR
Boccard et al. 201350 2b/3 Prospective Single Consecutive
Chamadoira et al. 201153
(conference abstract)
2a NR NR NR
Mundinger and Salomão
198057
2a/b NR NR NR
Owen et al. 200754 2a/b Prospective Single NR
Pereira et al. 201351 2b/3 Prospective Single Consecutive
Pereira et al. 201252
(conference abstract)
2a Prospective Multicentre Consecutive
Yamamoto et al. 200655 2a NR NR NR
Dorsal root ganglion stimulation
Eldabe et al. 201564,79 1/2a Retrospective Multicentre Consecutive: ‘all
patients treated
with DRG
neuromodulation’
Love-Jones et al. 201563
(conference abstract)
2a/b Prospective NR NR
Wahlstedt and Leljevahl 201365
(conference abstract)
2b Retrospective Single Appears to be
consecutive: ‘first
5 patients’ treated
continued
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Study intervention details and results are presented in Table 16. Only one61 of the three studies reported
on the frequency of stimulation used. Two studies59,60 reported using trial periods to evaluate MCS before
decisions were made on permanent implantation; both reported trial success in all patients. Across all three
studies in which there were around 2 years of follow-up, six patients were reported to have PLP reductions
of ≥ 70%, although in one patient pain relief was achieved only after repositioning of the electrodes. In
the study that reported separate results data for PLP ‘at rest’ and PLP ‘during activity’,60 the reductions for
the latter were notably lower. Three patients did not have an adequate response to MCS; the electrodes
were removed in two patients, and one patient discontinued treatment. Data were not reported for one
patient, who was at the 6-month follow-up point. Few data were reported on other outcomes. One
study60 reported ‘significant improvement’ in the activities of daily living scores in two patients, although
no actual results data were provided.
Deep brain stimulation The eight included DBS studies covered 55 PLP patients in total (see Table 13).
Sample sizes ranged from 3 to 14 patients. Most publications reported on studies that recruited patients
covering two or more chronic pain conditions, of which PLP patients were a subgroup.50,51,53–55,57
Consequently, PLP-specific data were sometimes not available for several baseline parameters (see Table 13)
and for some results; baseline PLP levels were available in only one study.51 In one of the SCS studies,71
two patients were treated with DBS, having failed treatment with SCS (see Spinal cord stimulation).
TABLE 15 Quality assessment results for the non-comparative group studies (continued )
Study IDEAL stagea
Prospective or
retrospective design
Single
centre/multicentre Recruitment
Spinal cord stimulation
Broggi et al. 199466 4 (included a
large cohort
and long-term
follow-up)
Retrospective Multicentre NR
Claeys & Horsch 199767 2a/b NR NR NR
De Caridi et al. 201668 2a/b NR Single NR
Devulder et al. 199069 2a NR – probably
Retrospective
Single Consecutive
Garcia-March et al. 198770 2b NR NR NR
Katayama et al. 200171 – Retrospective NR NR
Krainick et al. 197578 2b NR NR NR
Miles et al. 197477 2a NR Single NR
Miles and Lipton 197876 2a NR Single NR
Nittner 198273 (conference
abstract)
2a NR Single NR
Sanchez-Ledesma et al. 198974 2b Unclear – probably
retrospective
Single NR
Viswanathan et al. 201031 2a Retrospective Single NR
Wester 198775 2a/b Retrospective Single Consecutive
NR, not reported.
a A loose estimate of the stage of research, based on the IDEAL recommendation stages of surgical innovation.80
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TABLE 16 Motor cortex stimulation: intervention parameters and results of non-comparative group studies
Study Intervention parameters Results
Carroll et al.
200061
l Implantation of quadripolar electrode by
means of a two-stage surgical procedure
l Craniotomy undertaken 1 week before
definitive procedure
l Electrodes implanted extradurally. Bipolar
stimulation at 15–25 Hz used to identify
optimum position for electrodes
l Stimulation tested intraoperatively but no
trial period. Initial titration to determine
optimum stimulation parameters done
4–6 weeks after implantation
l Mean frequency (in two patients with pain
relief at titration): 50 Hz
l Two of three patients experienced pain relief
during postoperative titration of stimulation
parameters (4–6 weeks after surgery)
l Patient 5: 70% PLP relief at 23 months’ follow-up;
0% relief of stump pain. ‘Good’ pain relief (3) on a
0–5 scale
l Patient 8: 75% PLP relief in arm, 5% relief in
hand at 21 months’ follow-up
l Patient 9: no pain relief – discontinued owing to
technical failure
l Four-point verbal rating scale of pain intensity
and five-point rating scale of pain relief scale
measured but results not reported for all patients
l Adverse effects/complications:
¢ Patient 5: unacceptable tightness in
phantom leg when amplitude increased
(despite 100% relief of pain at higher
amplitude). Electrodes re-sited 1 year
7 months after intervention owing to
fractured lead because of trauma sustained
while rapidly elevating arms above head
¢ Patient 8: faulty IPG replaced 7 months after
intervention. Electrodes replaced 1 year after
intervention owing to fractured leads.
Secondary wound infection of neck and
scalp after electrode revision, required
antibiotics
¢ Patient 9: electrodes re-sited 6 months after
intervention. Technical failure because of
poor patient compliance. Patient had contact
with large magnetic field causing ID number
to be wiped from stimulator. Caused
damage to the IPG by repeatedly rotating
the pulse generator under his skin for first
titration session
Hosomi et al.
200859
l Test stimulation for 1 or 2 weeks before
permanent implantation
l Grid electrodes used to determine optimal
site for pain relief (M1 in all patients).
Resume electrodes implanted in
interhemispheric fissure for two patients,
subdural precentral gyrus surface for one
patient and both sites for one patient
l 90% VAS score reduction in one patient at
54 months’ follow-up. Electrodes removed in
two patients (at 6 months and 5 months).
< 6 months’ follow-up data available for
one patient
l Short-form MPQ also measured but results not
reported for PLP patients
Saitoh et al.
200062
l Craniotomy undertaken overlying the SSS
l Placement of four-electrode array in the
interhemispheric fissure. In one patient, a
second four-electrode array was placed
beside the SSS. Positioned in proximity to the
motor cortex that corresponded to the
affected limb
l Test period before permanent implantation
(length unclear). Stimulation delivered to
various areas no more than three times a
day. Monophasic square-wave pulses.
25–50 Hz. Usually applied continuously for
30 minutes
l VAS and MPQ classified as follows:
excellent = reduction in PLP by 80–100%;
good = reduction in PLP by 60–79%;
fair = reduction in PLP by 40–59%;
poor = < 40% reduction
l Both patients received permanent implant after
trial period
l Follow-up duration ranged from 6 to 26 months
for all patients (not just PLP)
l Patient 6: during test stimulation VAS = 2
(excellent). After 20 months, outcome recorded
as good
l Patient 8: during test stimulation VAS = 6 (fair).
After 6 months, outcome recorded as fair
continued
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The quality assessment results for the DBS studies are presented in Table 15. Five studies were undertaken
prospectively;50–52,54,58 although three of these studies were closely related, reporting on cohorts that
overlapped.51,52,58 Abreu et al.’s58 paper provides longer-term follow-up data for the Pereira et al.51 cohort
(and also adds a single patient). In four studies,53,55–57 it was unclear whether the studies were undertaken
prospectively or retrospectively. In four studies, patients50–52,58 were recruited consecutively. Only one study52
was reported as being multicentre. In terms of the IDEAL stages, most of the studies of DBS were at the
development/exploration stage, although three50,51,58 included some elements of the assessment stage.
Study intervention details and results are presented in Table 17. Five50–52,54,55 of the eight studies reported
stimulation frequency details. Seven studies50–54,56,58 used trial periods to evaluate DBS before decisions
were made on permanent implantation. In the remaining two studies,55,57 information on trial periods was
not reported. Most of the studies that mentioned trial periods reported on success rates – all were 100%.
For the four studies50–52,58 that prospectively recruited consecutive patients, the mean improvements in VAS
pain score in PLP patients after 1 year of follow-up ranged from 39% to 90%; three50–52 of these studies
reported on mean Short Form questionnaire – 36 items (SF-36) improvements, which ranged from 13% to
58%. It should be noted that the extremes of the ranges of these results are from the two related studies
by Pereira et al.;51,52 this notable difference in results may be attributable to greater clinician experience
and better patient selection in the smaller group that was studied later (see Table 17). One study58
followed patients for 3 years, reporting a statistically significant 67% median improvement in VAS pain
score (from baseline); SF-36 median improvement was 17% and was not statistically significant.
All of the other studies reported data on the number of PLP patients achieving a ≥ 50% improvement in
pain (or ≥ 60% in one study).55 Across these studies, after 1 or 2 years of follow-up, the proportion of
patients achieving a ≥ 50% improvement ranged from 50% to 100%. In the study that used the ≥ 60%
cut-off point, 8 out of 11 patients (73%) were responding to DBS at 1 year.55 Complication and adverse
event data, which were reported for whole study cohorts (rather than specifically for PLP), revealed
variation in incidence, ranging from no significant adverse events51 to 18% of patients needing
lead revisions.50
Spinal stimulation therapies
Of the interventions targeting the spinal area, we identified three studies of DRG stimulation63–65 and
14 studies of SCS.66–78
TABLE 16 Motor cortex stimulation: intervention parameters and results of non-comparative
group studies (continued )
Study Intervention parameters Results
Sol et al.
200160
l Craniotomy flap undertaken to expose the
dura overlying the sensorimotor cortex.
Four-contact electrode tightly sutured to the
dura at the location of the central sulcus and
functional motor area
l 1-week period of testing undertaken
l Mean follow-up duration: 27.3 months
l All patients obtained complete initial
improvement of PLP. At follow-up:
¢ Patient 1: progressive loss of effect after
4 months. Following repositioning of
electrode, patient had 80% pain relief on
VAS at rest, 20% during activity
¢ Patient 2: 100% pain relief on VAS at rest,
80% during activity
¢ Patient 3: 70% pain relief on VAS at rest,
40% during activity
¢ Patients 2 and 3 had ‘significant
improvement’ in activities of daily living
scores at follow-up (actual data were not
reported). No patients had postoperative
complications or side effects
ID, identification; IPG, implantable pulse generator; MPQ, McGill Pain Questionnaire; SSS, superior sagittal sinus.
SYSTEMATIC REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
TABLE 17 Deep brain stimulation: intervention parameters and results of non-comparative group studies
Study Intervention parameters Results
Abreu et al. 201758
(same cohort as
Pereira et al. 2013,51
with one additional
patient)
l Contralateral, ventroposterolateral nucleus
of the sensory thalamus targeted. Effect of
macrostimulation assessed from 2mm
above to 5 mm below the calculated
target to elicit paraesthesia or analgesia
l Quadripolar electrodes. Final electrode
position determined by intraoperative
clinical assessment that relied on
subjective reporting by awake patient
l 48-hour period of postoperative clinical
assessment before decision on whether or
not to permanently implant electrodes
l Initial frequency: 10 Hz in three patients,
20 Hz in two patients, 30 Hz in one
patient
l Frequency at 3 years: 10 Hz in four
patients, 15 Hz in one patient, 20 Hz in
one patient
l Follow-up duration of 3 years. All patients
received permanent implant (100% trial
success rate)
l At 1 year:
¢ median VAS score decreased from 6 to 1,
median improvement of 80% from
baseline; p= 0.02
¢ median UNWPS decreased from 63 to 9,
median improvement of 83% from
baseline; p= 0.04
¢ median BPI decreased from 11.5 to 2,
median improvement of 90% from
baseline; p= 0.02
¢ median SF-36 increased from 462 to
618, median improvement of 34% from
baseline; p= 0.40
l At 2 years:
¢ median VAS score = 0.3, median
improvement of 83% from baseline;
p= 0.003
¢ median UNWPS = 9, median
improvement of 83% from baseline;
p= 0.03
¢ median BPI = 1, median improvement of
91% from baseline; p = 0.003
¢ median SF-36 = 576, median
improvement of 23% from baseline;
p= 0.29
l At 3 years:
¢ median VAS score = 2, median
improvement of 67% from
baseline; p= 0.049
¢ median UNWPS = 31, median
improvement of 51% from
baseline; p= 0.32
¢ median BPI = 4, median improvement of
65% from baseline; p = 0.16
¢ median SF-36 = 655, median
improvement of 17% from baseline;
p= 0.24
l No surgical complications or side effects and
no need for electrode or implantable pulse
generator revisions up to 3 years
Bittar et al. 200556 l DBS of PVG and somatosensory thalamus.
Two patients: PVG only. One patient: PVG
and thalamic stimulation
l Implanted electrodes had four exposed
contacts, each 1.5 mm long, arranged
linearly with 1.5 mm in between. Location
adjusted to find site of greatest pain relief
l Several days of testing before generator
implanted
l At mean follow-up duration of 13.3 months,
the mean reduction of pain intensity was
62% (SD 7.4%, range 55–70%). Satisfactory
pain relief (≥ 50%) in all three patients.
Burning component of pain completely
alleviated in all three patients
l Statistically significant improvement in
quality-of-life measures (EQ-5D VAS 0–100).
Mean preoperative value: 43, mean
postoperative value: 68; p = 0.02
l SF-36 v-2 questionnaire and MPQ also
assessed – results not reported
continued
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TABLE 17 Deep brain stimulation: intervention parameters and results of non-comparative
group studies (continued )
Study Intervention parameters Results
Boccard et al.
201350
l DBS of either PVG or VPL thalamic nuclei
or both targets (contralateral to the
painful side)
l Quadripolar electrodes with 1.5 mm
spacing implanted. Final position
determined by intraoperative clinical
assessment reliant on subjective reporting
by awake patient
l Initial stimulation at 5–50 Hz
l 1-week trial, with targets trialled
individually then together for 1–2 days
l Mean follow-up duration: 32 months
l Nine of nine patients received a permanent
implant (100% trial success rate)
l After 3 months, mean pain reduction on
VAS was 52.5% (SD 30.3%; p= 0.06)
l Mean improvements at 1-year follow-up
(p-values for baseline comparisons):
¢ VAS score (n = 7) 38.7% (SD 20.5%,
p= 0.004)
¢ MPQ score (n = 7) 31.8% (SD 38.5%,
p= 0.04)
¢ SF-36 score (n = 8) 17.6% (SD 24.2%,
p= 0.09)
¢ EQ-5D score (n= 8) 31.7% (SD 11.0%,
p= 0.01)
¢ Health state (n= 7) 81.5% (SD 120.0%,
p= 0.005)
l Adverse event rates (in the broader cohort
of chronic pain patients): 42% needed
implantable pulse generator changes,
18% had lead revisions, 9% had infections,
7% needed device removal
Chamadoira et al.
201153 (conference
abstract)
l Electrodes implanted in somatosensory
thalamus
l Double-blind evaluation to test effect of
each electrode on its own as well as
combined stimulation with different
parameter settings before implantation of
stimulation device
l Two of the four PLP patients (50%) had
> 50% pain relief at 1 year. Other two
patients had ‘similar results’ at 6 months.
VAS, BPI, SF-36, MPQ and UWNPS all
measured but unclear which of these
measurements pain relief results referred to
l Quality of life: ‘a significant improvement in
all patients’
Mundinger and
Salomão 198057
l DBS of lemniscus medialis with inclusion
of the specific and unspecific
somatosensory nuclei in four patients
l DBS of centrum medianum in two patients
l DBS of medial pulvinar in one patient
l Mean follow-up duration for PLP patients:
21.4 months
l One of seven patients practically free of
pain (> 70% improvement), no analgesics,
completely fit to work, good general
condition (PLP and stump pain together)
l Four of seven patients had up to 70% pain
improvement, no analgesics but still slightly
handicapped owing to pain, fit to work
(PLP and stump pain together in one patient)
l Two of seven patients had up to 50% pain
improvement, no more analgesics or only
occasionally (PLP and stump pain together in
both patients)
l Complications in the broader group (n= 32):
six ‘technical’ and five ‘neurological’. Further
details provided in the publication
Owen et al. 200754 l DBS of the sensory thalamus and/or the
periventricular and periaqueductal
grey area
l 1-week trial stimulation before permanent
implantation. Stimulation frequency for all
patients (not available for just PLP) ranged
between 5 Hz and 50 Hz
l Follow-up duration for PLP patients not
reported; for all patients, mean was
44.5 months
l Seven of seven patients received permanent
implant (100% trial success rate)
l Mean improvement in VAS score of 51%
(SD 14%, range 18–74%) in six patients
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TABLE 17 Deep brain stimulation: intervention parameters and results of non-comparative
group studies (continued )
Study Intervention parameters Results
l Four of six patients (67%) had ≥ 50%
improvement
l MPQ also measured but results not reported
l Four-tiered categorisation of pain outcomes
not reported separately for PLP
l It appeared that one of the seven patients
was lost to follow-up
l Adverse events for whole cohort (n= 38):
wound infection needing prolonged course
of antibiotics in two patients. Electrode lead
fracture in one patient
Pereira et al. 201351
[patients are from
the same cohort as
Pereira et al. 201252
(conference
abstract)]
l Contralateral ventroposterolateral nucleus
of the sensory thalamus targeted
l After burr hole exposure, a radiofrequency
electrode impedance check was
undertaken to 10mm above target, then
DBS electrode insertion to target and
intraoperative C-arm radiographic
target confirmation
l Quadripolar electrodes with 0.5-mm
contacts spaced 1.5 mm apart. Final
electrode position determined by
intraoperative clinical assessment that
relied on subjective reporting by
awake patient
l Frequency: two patients, 10 Hz; two
patients, 20 Hz; one patient, 30 Hz
l 48-hour trial undertaken before decision
on permanent implantation
l Follow-up at 1 month, 3 months, 6 months
and 12 months
l Five of five patients received permanent
implant (100% trial success rate)
l Mean VAS score before DBS was 7.4; at
12 months it was 3
l Mean improvements at 12 month follow-up:
¢ VAS score: 90% (SD 10%; p< 0.001)
¢ SF-36: 58% (SD 97.9; p= 0.127)
¢ UWNPS: 80% (SD 13%; p< 0.001)
¢ BPI: 80% (SD 15%; p< 0.001)
l Statistically significant improvements in VAS
score at 1 and 6 months, in UWNPS at all
follow-up points and in BPI at all follow-up
points
l SF-36 statistically significantly improved
by 71% at 1 month (p= 0.013) but
non-significant results at all other follow-up
points
l No significant surgical complications. Side
effects were ‘unremarkable’
Pereira et al. 201252
(conference
abstract)
l DBS of the ventral posterolateral thalamus
and periaqueductal grey. In contralateral
positions in most patients
l Mean frequency: 22 Hz
l Follow-up at 1–3 months, 6 months and
12 months. 4-year follow-up for some patients
l All patients received permanent implant
l Mean VAS score reductions were 61% at
1–3 months and 57% at 1 year
l Mean SF-36 improvements were 22% at
1–3 months and 13% at 1 year
l 4-year data for four patients: improvements
of 36% for VAS and 11% for SF-36
l ‘Additional outcome scores’ also measured,
but results not reported
l Adverse effects: there were no operative
complications. Three patients received
electrode revisions (two owing to electrode
damage, one owing to overcome tolerance)
Yamamoto et al.
200655
l DBS of thalamic nucleus VC
l Implantation through burr hole. Electrodes
with four contact points placed so that the
most distal contact point was in the VC
and the most proximal in the thalamic
nucleus ventralis intermedius
l Stimulation frequency: 20–135 Hz
l Follow-up duration of 1 year
l 8 out of 11 patients (73%) achieved > 60%
pain reduction in VAS score
l Mean reduction in VAS score was 69%
l In two cases, pain completely disappeared
after long-term stimulation. It reappeared
after long-term cessation of DBS and patients
underwent DBS again which subsequently
reduced the pain
BPI, Brief Pain Inventory; EQ-5D, EuroQol-5 Dimensions; MPQ, McGill Pain Questionnaire; PVG, periventricular grey matter;
SD, standard deviation; UWNPS, University of Washington Neuropathic Pain Score; VC, ventralis caudalis; VPL, ventral
posterior lateral.
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Dorsal root ganglion stimulation
The largest of the three studies of DRG stimulation (see Table 14),63 which was available only as a conference
abstract, reported on patients with PLP and/or stump pain but data were not reported separately for PLP and
stump pain patients. This somewhat limits the applicability of this study’s results to a PLP population (as it
appears likely that some patients did not have PLP, only stump pain). However, the mean baseline pain in
this study (86 on a 0–100 VAS) was similar to the mean baseline pain in a study in which all eight patients
had PLP (84 on a 0–100 VAS).64 The remaining study was of two patients.65 The quality assessment results
are presented in Table 15. One study recruited patients prospectively,63 one was retrospective64 and the
recruitment method details were not reported in one study.65 Two of the three studies reported recruiting
patients consecutively.64,65 One study was multicentre,64 one was based at a single centre65 and one did
not report details.63 In terms of the IDEAL stages, all three studies of DRG were at the development/
exploration stage.
Study intervention details and results are presented in Table 18. Only one study64 reported on the
frequency of stimulation used. All three studies reported use of a trial period before full implantation.
Two studies reported on the results of trial periods, with high success rates of 73%63 and 100%.64 One
study64 reported results showing that the amount of pain relief from DRG stimulation varied widely across
patients, and sometimes waned over time. In the study that presented results of stump-pain-only patients
together with PLP patients,63 6 out of 16 permanently implanted patients (38%) had ≥ 50% pain relief
at 6 months. Quality of life was assessed in two studies, both using the EuroQol-5 Dimensions (EQ-5D).
The retrospective study64 had data available for two of the eight patients, reporting only that ‘significant
improvement’ was observed. The other study63 reported that at 6 months the mean EQ-5D index score
improved by around 0.3, although more patients contributed data to the before-treatment mean score
than to the after-treatment mean score so the result is likely to have been affected by attrition bias.
A conference abstract65 reported on DRG stimulation used in patients with various pain conditions.
Two patients had PLP and stump pain, but results were only reported for one patient, and only up to
1 week of follow-up. Overall, very few complications were reported across studies.
Spinal cord stimulation
Sample sizes across the 14 studies of SCS ranged from 2 to 26 patients, although all but the largest study
had sample sizes of < 10 patients. Ninety-six patients were studied in total. Baseline pain was only clearly
reported in one study.75 In another study,72 reported as a conference abstract, baseline VAS scores were
reported on a graph and were > 7.5 for all five patients. The quality assessment results are presented
in Table 15. Five studies were retrospective66,71,72,75 and the timing of recruitment was unclear in six
studies.67–70,73,74 Only two studies reported that patients were included consecutively.69,75 One publication
was based on a multicentre study66 and eight were single-centre studies.68,69,73–77 Although it appeared
that several of the remaining studies were at single centres, this was not clearly reported as such. Despite
the fact that the earliest of these studies was published in 1974, in terms of the IDEAL stages, most of
the studies of SCS were at the development/exploration stage, with the exception of one retrospective
multicentre study of epidural SCS published in 1994,66 which included a large cohort and long-term
follow-up.
Study intervention details and results are presented in Table 19. Only 267,70 of the 14 studies reported on
the frequency of stimulation used. Few studies reported on trial period success rates. Three studies,71,72
all with follow-up durations of ≥ 1 year, reported that all or most patients had positive results with PLP
reductions of ≥ 60% or ≥ 80%. Five studies,67,70,73,74,77 reporting at varying follow-up time points, had
more mixed results with variation in responses across and within patients (i.e. pain relief waning over time).
Six studies66,68,69,75,76,78 reported either very limited or very short-term results data on PLP reduction.
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TABLE 18 Dorsal root ganglion stimulation: intervention parameters and results of non-comparative group studies
Study Intervention parameters Results
Eldabe et al.
201564,79
Narrow quadripolar neurostimulation leads
using an epidural approach and curved stylets.
Stimulating contacts placed near relevant DRGs
based on individual pain distributions. All
patients underwent a multiple-day period of
trial stimulation: ≥ 50% pain relief was
considered successful. Frequency: 20–40 Hz
Mean follow-up duration: 14.4 months. Mean
VAS score at last follow-up was 38.9 (SD 27.1).
Mean of 52.0% (SD 31.9%) pain reduction
(stump and/or PLP)
Eight out of eight patients received a
permanent implant (100% trial success rate)
% pain relief for the four patients who had only
PLP: 0% (at 24 months), < 20% (at 24 months),
29% (at 13 months), 100% (at 5 months)
Five patients had good pain relief outcomes.
Three patients experienced poor outcomes,
despite good initial results
EQ-5D assessed in two patients: ‘significant
improvement’ reported but numbers not
presented. No complications were reported for
any of the patients
Love-Jones et al.
201563 (conference
abstract)
Specifically designed quadripolar leads placed
in the epidural space near the relevant DRG
following standard procedures
Patients underwent trial period
Results not reported separately for PLP and
stump pain
16 of 22 patients received a permanent implant
(73% trial success rate)
At 6 months, VAS score was reduced to 37.8
(SD 35.4) (n= 10)
Six of 16 permanently implanted patients
reported ≥ 50% pain relief
EQ-5D index score improved from 0.27 (SD
0.29) (n= 14) to 0.60 (SD 0.28) (n= 10);
p< 0.05
Total weighted rank and number of words
chosen in MPQ improved from 44.9 (SD 13.4)
to 19.0 (SD 17.3) and 14.9 (SD 4.61) to 7.3
(SD 5.7), respectively; p< 0.05
One patient was explanted for inadequate pain
relief after 6 months
Wahlstedt and
Leljevahl 201365
(conference
abstract)
Patients underwent a trial in which specifically
designed leads were implanted at the target
DRGs. Following successful trial, patients
received a fully implantable neuromodulation
device
After 1 week, PLP improved in one patient by
100%; results not reported for 1-month time
point
Results not reported for the second PLP patient
EQ-5D, EuroQol-5 Dimensions; MPQ, McGill Pain Questionnaire; SD, standard deviation.
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TABLE 19 Spinal cord stimulation: intervention parameters and results of non-comparative group studies
Study Intervention parameters Results
Broggi et al.
199466
Epidural SCS
Unipolar or multipolar lead implant to
dorsal or cervical area. Stimulation test
period: mean 17 days, range 8–42 days
(for all chronic pain patients)
Verbal pain intensity scale (mild to excruciating), VAS
and ‘life standard’ all measured, but very limited data
reported specifically for PLP patients
88.5% of PLP patients had pain relief and requested
system internalisation
Complication rate in whole cohort (non-malignant
chronic pain) (n= 410): dislocation of leads 4%, lead
breakage 2%, infections 1%
Claeys and
Horsch 199767
Quadripolar lead placed into epidural space
by percutaneous lumbar puncture. Lead
advanced under radioscopic control to level
of T11–12
1-week trial period before implantation of
IPG if adequate pain relief
Usual initial frequency settings: 70–120 Hz
Stimulation could be given continuously or
intermittently
At 3 months’ follow-up, pain relief on VAS was 77.6%
in five patients and 57.3% in other two patients
At mean follow-up duration of 29.5 months:
l Stable successful results in three patients (mean
78.7% pain relief), diminished positive effects in
two patients (mean 56.6%), poor pain relief in two
patients (mean 24.3%)
l ‘Same effects on pain relief recorded by a
verbal scale’
l No implantation-related complications
De Caridi et al.
201668
2-octrode electrode lead placed in median
peridural space. Double paramedian
approach with a C-arm
Test stimulation performed for 1 week.
Permanent SCS therapy if pain maintained
to within 20–30/100 mm on VAS, use of
opiate analgesics decreased by 50%,
increase in transcutaneous oxygen pressure
of > 75% on the right foot
Patient 1: > 90/100 mm before intervention. 3 months
after intervention, pain was ‘maintained within
30/100 mm’
Patient 2: baseline PLP NR. 3 months after intervention,
pain ‘maintained within 30/100 mm’
Patient 3: baseline PLP NR. 3 months after intervention,
pain ‘maintained within 30/100 mm’
Devulder et al.
199069
Minimum 2-week trial procedure.
Monopolar electrodes introduced
percutaneously in the epidural space during
trial. Located at a level that produced
electrical stimulation paraesthesia in the
painful area
If trial procedure was positive after at least
2 weeks, multipolar
Resume electrodes were neurosurgically
implanted for permanent system
Follow-up duration not reported
Three of five patients had good pain relief with no need
for medication
One of five patients had little pain relief and needed
narcotic analgesics
One of five patients no longer used the stimulation
system
Complications in the broader population (n= 45):
23 patients required reintervention, with migration and
breakage of the electrode being the commonest causes
Garcia-March
et al. 198770
Bipolar stimulation used. Two stimulating
electrodes percutaneously introduced into
epidural space and advanced to a cervical
level where stimulation provoked a tingling
sensation in the painful region
Trial stimulation for 2 weeks at 80–120 Hz
Permanently implanted if pain relief
experienced
Two of two patients received permanent implant
(100% trial success rate)
‘Fair’ defined as 25–75% pain relief, analgesics
required, unable to return to work or social life. ‘Poor’
defined as < 25% pain relief, narcotics required and
other invasive neurosurgical treatment required
Fair early results in both patients, with poor results at
19 months’ follow-up for one patient and 14 months
for the other
There were no adverse effects
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TABLE 19 Spinal cord stimulation: intervention parameters and results of non-comparative group studies (continued )
Study Intervention parameters Results
Katayama et al.
200171
All patients tried percutaneous SCS. If it
failed to reduce pain, patients were
considered for DBS of thalamic nucleus
ventralis caudalis or MCS
DBS performed with four contact
electrodes, 1.5 mm in length, each
separated by 1.5 mm
SCS and MCS both performed with four
plate electrodes, 5 mm in diameter, each
separated by 5 mm, placed epidurally
through a small laminectomy or craniotomy
If pain control was achieved, chronic
stimulation was performed
Follow-up duration range (for all 19 patients, not just
non-BPA group): 2–18 years
Six of eight patients achieved satisfactory pain control
(defined as ≥ 80% pain reduction on VAS) with SCS
Two of two patients achieved satisfactory pain control
with DBS
One patient underwent DBS and MCS, with 30–100%
pain reduction on VAS with DBS and 10–20% pain
reduction with MCS
Krainick et al.
197578
Test procedure of percutaneous stimulation
of the spinal cord using floating electrode
for 3 days. Puncture done mostly in lumbar
area and threaded upwards to the desired
level. Electrodes implanted subdurally or
endodurally
DCS implanted after trial in three of four patients
(75% trial success rate). One of four patients
experienced no pain relief
Postoperative results at discharge:
l 50–75% pain relief in one of three patients
(PLP and stump pain)
l 75–100% pain relief in one of three patients
l The other patient experienced operative
complications and the DCS was explanted
Miles et al.
197477
Posterior column implantation. Electrode
site was cervical (four patients) or thoracic
(one patient). Some patients had a trial
period (details unclear)
Mean follow-up duration: 5.8 months
No pain relief in two of five patients
Good relief and no analgesics in three of five patients
Miles and Lipton
197876
Stimulation done percutaneously during test
period, with electrode(s) inserted into the
extradural space (two electrodes with tips
2–5 cm apart) or subarachnoid space.
Tested for up to several weeks in extradural
position or 2–3 days in subarachnoid space
Decision to perform implant based on
several tests
Six of nine patients had excellent relief of pain with the
requirement of no analgesics
One of nine patients had some relief of pain with the
need for occasional simple analgesics
Two of nine patients had no relief of pain
The follow-up time point for these results was not
reported
Naidu et al.
201372
(conference
abstract)
Clinical examination to map out the
dermatome, target selection entirely
directed by segment that would refer
sensation to the phantom
Multicolumn paddle electrodes. Multiple
stimulation configuration options used
Average follow-up duration of approximately
12 months
All patients experienced a > 60% reduction in VAS
score
Mean VAS (0–10) score reduction was 7.3
No serious complications were reported
continued
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TABLE 19 Spinal cord stimulation: intervention parameters and results of non-comparative group studies (continued )
Study Intervention parameters Results
Nittner 198273 Epidural implantation of electrodes
Location of electrodes varied. Authors
found optimal results when tip of active
electrode was between D10 and L1.
Unipolar or bipolar implantation of
electrodes depending on case
Six of seven patients had ‘excellent’ results and the
other patient had ‘good’ results at time of operation.
Postsurgery pain results:
l Patient 1: ‘satisfactory’ at 3 weeks, < 30%
improvement
l Patient 2: ‘satisfactory’ at 1-month follow-up,
< 30% improvement. Removal of electrodes at
2 months
l Patient 3: ‘good’ at 1 month, 70% improvement
l Patient 4: ‘good’ at 3 months, 50% improvement.
Recurrence at 6 months
l Patient 5: ‘excellent’ at 3 months, 100%
improvement. < 30% improvement at 1 year
l Patient 6: ‘excellent’ at 9 months, 100%
improvement
l Patient 7: no follow-up results recorded
Sanchez-
Ledesma et al.
198974
One or two standard SCS leads introduced
percutaneously into the epidural space
Patients underwent 2 weeks of trial
stimulation. If patients had a positive
response involving pain remission > 50%,
the device was permanently implanted
Follow-up duration for PLP patients not reported; for all
patients, mean of 5.5 years
Three of six patients had positive response to trial
stimulation and were permanently implanted
Two of three patients had 0–25% long-lasting pain
relief
One of three patients had 50–75% long-lasting pain
relief
There were no serious complications and two minor
complications in the broader population (n= 49)
Viswanathan
et al. 201031
Percutaneous octopolar leads
All patients underwent a 1-week trial of
stimulation. Permanent implantation was
performed if 50% reduction in pain
experienced
All patients reported pain relief of > 80%
postoperatively
Mean follow-up duration was 28 months
Three patients reported a 2-point decrease in their usual
amount of pain on numerical pain scale and one patient
reported no change
On 11-point BPI scale assessing other symptomology
along 10 dimensions, three patients had a decrease in
their total symptom score by 13, 14 and 4 points,
respectively. One patient reported an increase by
5 points in total symptom score (owing to recurrent
cancer and treatment)
Complications: one patient developed an allergic
dermatitis to the generator requiring revision with a
GORE-TEX® (W.L. Core & Associates, Inc., Flagstaff, AZ,
USA) pouch. One patient had a surgical site infection
following routine changing of the implantable pulse
generator. It required removal of the SCS system and
treatment with antibiotics
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None of the studies reported on quality-of-life measures, although one study’s70 assessment of treatment
response broadly considered whether or not patients had ‘returned to work or social life’ (both patients
studied achieved ‘poor’ results). When reported, complications were infrequent in most studies, although
one study69 reported that in the broader chronic pain population of 45 patients, just over half required
reintervention, mostly owing to migration and breakage of the electrode. Another publication75 reported
that in its broader study population, 13 out of 30 patients needed reoperation owing to technical issues.
Summary
Although several of the non-comparative group studies reported results that appeared impressive in
the short term (many patients had reductions in PLP sufficient to warrant permanent implantation), the
effects diminish over time in some patients, with implants sometimes having to be removed. Nevertheless,
it appears that some patients do benefit in the longer term from invasive neurostimulation therapies,
although most studies did not have follow-up data beyond around 2 years.
Notwithstanding these results, their meaning – to the wider chronic PLP population – should be interpreted
with caution because many studies had important methodological and/or reporting limitations. Results from
uncontrolled studies are often inherently unreliable, being prone to several types of bias. For example, few
studies reported recruiting patients consecutively, a useful method for minimising selection bias. Within this
fundamental limitation, there were further methodological issues. Few studies reported having a prospective
design, which would ensure consistency of outcome data. Only three studies were multicentred; the results
of single-centre studies have limited generalisability to other centres, particularly for surgical interventions
such as these, in which factors (such as surgeon experience and parameter preferences) can affect results
considerably. Some studies did not present results for outcomes that were mentioned in their methods
sections. Although such suboptimal reporting of results could be attributable to a lack of space (especially
in older publications), it may also indicate the presence of reporting biases that highlight more impressive
results and suppress less impressive ones. Few studies reported data on quality of life or activities of daily
living – outcomes that are key in demonstrating the true value of interventions for chronic pain. Adequate
stimulation parameter data were sometimes not reported, making the replication of procedures by other
investigators difficult. Reflecting the limitations of these studies in terms of the IDEAL stages, none of
these neurostimulation therapy interventions has been fully developed and properly evaluated for
clinical effectiveness.
TABLE 19 Spinal cord stimulation: intervention parameters and results of non-comparative group studies (continued )
Study Intervention parameters Results
Wester 198775 Wire electrodes introduced into dorsal
epidural space through epidural needles.
Located to give tingling sensation in the
pain area
Trial period of 1 week. If patient reported
promising pain reduction, the system was
internalised
Follow-up duration for PLP patients not reported. For all
patients, median of 15 months, range 4–60 months
Five of five patients received permanent implant
(100% trial success rate)
Four PLP patients were still wearing the system at
follow-up (one of them regularly). One patient died
before follow-up
In the four patients alive at follow-up, pain intensity
before surgery was 2.5 (on a scale of 3 = strong,
2=moderate, 1=weak). At follow-up, pain intensity
was 2.1 with DCS and 2.6 without DCS. The ‘pain
reducing effect’ was rated as 0.5 on a scale of 0
(no effect) to 3 (good effect)
Complications in broader population (n= 30):
reoperation in 13 patients owing to technical issues
BPA, brachial plexus avulsion; BPI, Brief Pain Inventory; DCS, dorsal column stimulation; IPG, implantable pulse generator;
NR, not reported.
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The reporting issues were not helped by the fact that many studies were of heterogeneous populations with
chronic pain, only a subgroup of which had PLP. Consequently, in many studies, baseline data on important
variables, such as time since amputation and PLP intensity, were not available, making it difficult to interpret
results. Results data specific to PLP patients were also sometimes minimally reported. Moreover, even when
it was clear that patients had PLP, many studies were not clear on whether or not patients also had stump
pain (in addition to PLP). It is likely that in some studies patients were reporting on overall pain relief
reductions (i.e. PLP and stump pain together). This is important because neurostimulation interventions may
have different effects on PLP compared with stump pain, and results from the larger epidemiology studies in
our review indicated that stump pain may be prevalent in around half to two-thirds of amputees (whose
amputations were undertaken many years ago). The complexities involved in assessing and interpreting pain
outcomes further highlight the importance of the need to also assess quality-of-life outcomes.
The limitations evident in most of the non-comparative studies make it very difficult to attempt to compare
results across interventions and studies. Differences in results might be a consequence of variation in
patient, intervention or methodological parameters, rather than differences in treatment effect.
Case reports
There were 18 individual cases of PLP patients treated with an invasive brain or spinal stimulation therapy
reported in 17 papers that met the inclusion criteria (Table 20). Most were published as individual case
reports, although several were part of larger single-group studies (including multiple case reports) that
included only one patient with PLP.81,83,85,96 Five of the cases84,89–91,97 were reported only as conference
abstracts.
There were six case reports on SCS,82,84,88,90–92 six on MCS81,86,93–96 and four on DBS.83,85,87,97 There was also
one case report of SCS and DRG stimulation being undertaken simultaneously89 and one of MCS followed
by DBS.92 Follow-up time was at least a few months in most reports and several years in many. There was
one study of DBS that had only 1 week of follow-up.97 The follow-up time was 6 weeks in both a study of
MCS86 and the study of simultaneous SCS and DRG stimulation.89
The results of the case reports were generally positive, as would be expected with individual cases that the
authors have selected to publish. A few studies reported adverse events. One patient undergoing SCS
experienced pain caused by lead disposition.91 Complications associated with MCS were reported: one
patient experienced severe dysarthria and dysesthesias a few days after the operation, until modifications
to the stimulation were made;96 in another case, a patient experienced wound infection complications
from the replacement of an electrode 1 year after the initial surgery and vocal arrest and seizure during
high-voltage stimulation 2 years after surgery.93 One further study reported that electrode revision was
needed after SCS.82
Epidemiology studies
Of the 21 epidemiology studies of amputees included in the review, eight had a longitudinal design98–105
and 13 had a cross-sectional design.9,10,106–116
Longitudinal studies
Characteristics of longitudinal studies
Table 21 shows the characteristics of the populations in the longitudinal studies. Six studies had a prospective
design98,100,102–105 and two were retrospective.99,101 In the prospective studies, patients were mostly recruited
via hospitals and prosthetic fitting centres. Other than one retrospective mailed survey,99 all studies involved
interviews, sometimes combined with measurement or review of medical records. Three of the studies took
place in the UK,99,103,105 two in the rest of Europe102,104 and one each in Canada,100 the USA98 and Turkey.101
The number of participants varied from 11 in one study100 to 176 in the mailed survey,99 although most
studies included > 50 participants. The proportion of amputees who had PLP varied between studies
(and across time points) and ranged from 45% to 92%.
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TABLE 20 Details of case report studies
Study
Characteristics (age, time since
amputation, baseline PLP) Intervention
Duration of
treatment follow-up Results
Buchanan et al. 201481 Age (years): 56
Male
Above elbow amputation as a result
of trauma
Time since amputation NR
Medically refractory pain, 2 years
Baseline PLP on VAS (0–10): 9
MCS 3 months 3-month follow-up postoperative VAS scores = 6.5,
–0.28% change from preoperative VAS
Bunch et al. 201582 Age (years): 57
Male
Bilateral lower-limb amputation as a
result of infection
Time since amputation NR
Baseline PLP and stump pain on
VAS (0–10): 6
SCS (SCS system implanted pre
amputation for back pain did not
provide PLP relief and was changed
to constant current system with
additional leads)
12 months 90% pain reduction (PLP, stump pain and back
pain) during stimulation immediately after
operation and at 14-day follow-up
Lead migration leading to lack of coverage in one
limb at 3 months
90% pain reduction after revision
Sustained coverage of painful areas at 12 months
(NR if 12 months after initial procedure or revision)
Green et al. 200483 Age (years): 53
Male
Lower-limb amputation
Time since amputation NR
Baseline PLP on VAS (0–100): 81
DBS (PVG) 6 months PLP on VAS at 6 months reduced from 81 to 68
(p< 0.01 between baseline and 6 months)
MPQ score reduced from 26 at baseline to 19 at
6 months (p > 0.05)
Randomised N-of-1 trial results: mean PLP on VAS
was 48 when stimulator on, 46 when stimulator
off (p = 0.89)
Patient correctly guessed whether stimulator was
on or off 5 out of 10 times. No complications
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TABLE 20 Details of case report studies (continued )
Study
Characteristics (age, time since
amputation, baseline PLP) Intervention
Duration of
treatment follow-up Results
Hoffman and Sachdeva
201584 (conference
abstract)
Age (years): 52
Male
Lower-limb amputation as a result
of infection
Time since amputation NR
Baseline PLP NR
SCS > 1 year 80% pain relief of residual limb pain and PLP at
postoperative visit
Ongoing relief at approximately 1 year, except for
phantom foot
> 80% pain relief after implantation of additional
lead
Hollingworth et al. 201785 Age (years): 35
Female
Above elbow amputation as a result
of trauma
Time since amputation NR
Baseline PLP on VAS (0–100): 94
DBS 3 years VAS score at 3 years’ follow-up: 56
Patient no longer reliant on hot compress,
allowing return to independent living
Koppelstaetter et al.
200786
Age (years): 49
Male
30 years since amputation
Duration of pain: 28 years
Baseline PLP on VAS: 8 (assume out
of 10)
MCS 6 weeks 70% pain reduction on VAS
Effect immediate and persisting up to longest
follow-up (6 weeks)
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Study
Characteristics (age, time since
amputation, baseline PLP) Intervention
Duration of
treatment follow-up Results
Kringelbach et al. 200787 Age (years): 58
Male
Above the knee amputation as a
result of infection
4 years since amputation
Baseline PLP NR
DBS (PVG/PAG) NR Post-treatment improvement measured by MPQ –
reduction in pain score by 74%
With stimulation on VAS = 4.68
Lee et al. 201688 Age (years): 46
Male
Above knee amputation as a result
of infection
3 years since amputation
Baseline PLP on VAS (0–10): 7–8
SCS (specifically spinal cauda equina
stimulation)
5 months PLP maintained at 2–3 on VAS during 5 months’
follow-up
PLP sometimes increased to 4–5 on VAS
Mills and Helm 201689
(conference abstract)
Age (years): 56
Female
Below knee amputation as a result
of trauma
Duration of PLP: 3 years
Baseline PLP NR
SCS and DRG stimulation
(simultaneously)
6 weeks During 5-day trial, 50% relief of PLP with SCS
and 80% with DRG
75% improvement with DRG at 6 weeks’
follow-up
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TABLE 20 Details of case report studies (continued )
Study
Characteristics (age, time since
amputation, baseline PLP) Intervention
Duration of
treatment follow-up Results
Mubarak et al. 201190
(conference abstract)
Age (years): 35
Male
Hand amputation as a result
of trauma
Refractory to treatment for 5 months
including stellate ganglion blocks
Baseline PLP NR
SCS 6 months Patient-reported PLP (VAS) reduced by > 50%
at 1, 3 and 6 months
Mudrakouski et al. 201691
(conference abstract)
Age (years): 36
Male
Below elbow amputation as a result
of trauma
8 years since amputation
Baseline PLP NR
SCS 2 years 100% pain relief for 6 months
Effect gradually diminished with no pain control
after 2 years and stimulation causing excruciating
pain owing to lead disposition
Very good pain control from trial of high-
frequency stimulation despite lead disposition
Nandi et al. 200492 Age (years): 56
Female
Above knee amputation for
infection
≈4 years since amputation
Baseline PLP on VAS (0–10): 9.4
SCS 2 years VAS score improved from 9.4 (SD 0.89) to 1.0
(SD 0.7); p< 0.001. Time of poststimulation VAS
measurement not reported but pain relief was
‘sustained’ at time of last follow-up 2 years after
intervention
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Study
Characteristics (age, time since
amputation, baseline PLP) Intervention
Duration of
treatment follow-up Results
Nandi et al. 200492 Age (years): 51
Male
Below knee amputation for
peripheral vascular disease
≈4 years since amputation (MCS),
≈8 years since amputation (DBS)
Baseline PLP on VAS (0–10): 8.9
before MCS, 8.4 before DBS
MCS followed by DBS 4 years of MCS
NR for DBS
With MCS, VAS score improved from 8.9 (SD 0.73)
to 1.9 (SD 0.56) (p< 0.001) (time of measurement
NR). Rapid decrease in pain relief occurred over
1 month after 4 years of MCS
With DBS, VAS score improved from 8.4 (SD 0.96)
to 2 (SD 0.81) (p< 0.001). Effect has been ‘stable’
for 1 year at last follow-up
Pereira et al. 201593 Age (years): 56
Female
Amputation at shoulder for chronic
pain (trauma?)
> 10 years since amputation
Baseline PLP on VAS (0–10): 9
MCS 16 years PLP reduced by 78% to 2 on VAS at 6 months
Pain reduced by 75% from 8 with stimulation off
to 2 with stimulation on at 16 years
Improvements in MPQ and activities of daily living
Adverse events:
l Electrode replacement at 1 year with wound
infection complications
l Vocal arrest and seizure with high voltage
stimulation at 2 years
l Several revisions and replacements of
electrodes/IPG required
Roux et al. 200194 Age (years): 45
Male
Above elbow amputation as a result
of trauma
2 years since amputation
Baseline PLP NR
MCS 10 months VAS measure for pain reduction. Baseline VAS
score NR
Postoperatively reported 70% reduction in PLP
VAS score, and remained stable with adjustment
to follow-up at 3 and 10 months
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TABLE 20 Details of case report studies (continued )
Study
Characteristics (age, time since
amputation, baseline PLP) Intervention
Duration of
treatment follow-up Results
Saitoh et al. 199995 Age (years): 62
Male
Lower leg amputation resulting
from trauma and subsequent
necrosis
6.5 years since amputation
Baseline PLP on VAS (0–10) = 9
MCS 1 year Test stimulation produced a reduction in PLP VAS
score from baseline = 9 to post treatment = 2
At 12-month follow-up, pain relief was still effective
Sakas et al. 201196 Age (years): 44
Male
Above elbow amputation as a result
of trauma
11 years since amputation
Previous cervical cord stimulation
unsuccessful and removed after
5 months
Baseline PLP NR
MCS 9 months 2 days postoperative PLP improved by 60%
Modifications required owing to severe dysarthria
and dysesthesias
Day 10 postoperative bifocal stimulation resulted
in 90% improvement in PLP
At 9-month follow-up, patient virtually pain free
Sims-Williams et al. 201397
(conference abstract)
Female
Further characteristics NR
DBS (combined PVG/PAG) 1 week Created warmth that completely resolved the cold
pain felt
Parafascicular stimulation resulted in telescoping of
phantom limb from its previously contracted flexed
position
Pain and amputation stump allodynia improved by
50% (method of measurement NR)
IPG, implantable pulse generator; MPQ, McGill Pain Questionnaire; NR, not reported; PAG periaqueductal grey; PVG, periventricular grey matter; SD, standard deviation.
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TABLE 21 Characteristics of longitudinal epidemiology studies
Study Type of study Population (means unless otherwise indicated)
Hanley et al.
200798
Prospective study
Recruitment from consecutive admissions to
trauma hospital, as part of RCT
Face-to-face interviews and telephone
interviews
Setting: USA
N included (participation rate): 57 (66%)
% with PLP: for 4–5 days, 67%; for 6 months, 69%;
for 1 year, 73%; for 2 years, 62%
Age (years): 44
% male: 68
Amputation sites: below knee, 74%; above knee, 14%;
midfoot, 5%; through knee, 4%; other, 3%
Amputation causes: trauma, 70%; diabetes mellitus,
16%; infection, 5%; vascular disease, 4%; other, 5%
Time since amputation: 2 years of follow-up
% with prosthesis: NR
Comorbidities: 66% had chronic residual limb pain
Houghton et al.
199499
Retrospective, mailed survey Setting: UK
N included (participation rate): 176 (52%)
% with PLP: 78
Age (years): around 70
% male: NR
Amputation sites: below knee, 55%; above knee, 42%;
through knee, 3%
Amputation causes: trauma (including surgery for
tumours), 56%; vascular, 44%
Time since amputation (years): above knee, 10;a
below knee, 6.8;a through knee, 9.5a
% with prosthesis: 100
Comorbidities: NR
Hunter et al.
2008100
Prospective study but initial measurements
taken as part of other studies
Face-to-face interviews and measurement
Setting: Canada
N included (participation rate): 11 (79%)
% with PLP: initial, 72%; follow-up, 63%
Age (years): 35
% male: 91
Amputation site: below shoulder, 100%
Amputation cause: trauma, 100%
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TABLE 21 Characteristics of longitudinal epidemiology studies (continued )
Study Type of study Population (means unless otherwise indicated)
Time since amputation (mean, years): 2.4 (at follow-up)
% with prosthesis: 100 (at follow-up)
Comorbidities: 91% had stump pain
Kelle et al.
2017101
Retrospective review of records combined
with cross-sectional interviews
Setting: Turkey
N included (participation rate): 101 (47%)
% with PLP: EPP, 90%; 6 months, 45%
Age (years): 58
% male: 77
Amputation sites: above knee, including knee
disarticulation, 25%; below knee to ankle, 40%; below
ankle, 35%
Amputation causes: diabetes mellitus, 38%; trauma,
37%; vascular disease, 12%; cancer, 6%; infection,
4%; other, 3%
Time since amputation (years): not clear but between
6 months and 3 years before interview
% with prosthesis: NR
Comorbidities: 27% had stump pain at 6 months
Nikolajsen et al.
1997102
Prospective study (although pain questions
were retrospective for time period since last
interview) Recruitment from RCT cohort.
Interviews
Setting: Denmark
N included (participation rate): 56 (36%). 17 patients
(30%) died during follow-up. Four patients excluded
from analysis – had re-amputation after first follow-up
% with PLP: 1 week (n= 54), 67%; 3 months (n = 37),
68%; 6 months (n= 36), 75%
Age (years): 72a
% male: 59
Amputation sites: below knee, 55%; above knee, 32%;
through knee, 13%
Amputation causes: all peripheral vascular disease or
diabetic ulcers
Time since amputation (years): 0.5 (follow-up)
% with prosthesis: NR
Comorbidities: 43% diabetes mellitus, 18% previous
amputation, 19% stump pain (at 3 months)
Parkes 1973103 Prospective study
Recruitment from limb fitting centre.
Face-to-face interviews
Setting: UK
N included (participation rate): 46 (87%)
% with PLP: 3–4 weeks, 85%; 13 months, 61%
Age (years): NR (all under 70 years)
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TABLE 21 Characteristics of longitudinal epidemiology studies (continued )
Study Type of study Population (means unless otherwise indicated)
% male: 80
Amputation site: NR
Amputation cause: NR
Time since amputation (years): 1.1 (follow-up)
% with prosthesis: 100
Comorbidities: NR
Pohjolainen
1991104
Prospective study
Recruitment of consecutive patients sent for
prosthetic fitting
Face-to-face interviews, examinations and
evaluation of medical records
Setting: Finland
N included (participation rate): 155 (NR). 16 patients
(10%) died before follow-up
% with PLP: initial assessment, 59%; 1 year (n= 124),
53%
Age (years): 63
% male: 72
Amputation sites: below knee, 60%; above knee, 40%
Amputation causes: vascular disease, 81%; trauma,
10%; tumour, 6%; other, 3%
Time since amputation (years): 1 (follow-up)
% with prosthesis: 100
Comorbidities: 30% had problems in contralateral leg
at initial assessment
Richardson et al.
2006105
Prospective study. Recruitment from one
hospital prior to amputation. Interviews
Setting: UK
N included (participation rate): 59 (89%). Seven patients
(12%) died before follow-up
% with PLP: week 1, 92%; 6 months (n= 52), 79%
Age (years): 64
% male: 63
Amputation sites: below knee, 46%; above knee, 49%;
bilateral below knee, 3%; bilateral above knee, 2%
Amputation cause: all peripheral vascular disease
Time since amputation (years): 0.5 (follow-up)
% with prosthesis: NR
Comorbidities: 51% had stump pain (at 6 months)
EPP, early postoperative period; N, number of amputees; NR, not reported.
a Median.
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When reported, the average age of participants ranged from 35 to 72 years and most were male (ranging
from 59% to 91% of study participants). Most of the studies included only patients with lower-limb
amputation, except for one study that included patients with only below-shoulder amputations100 and one
that did not report this information.103 All or most patients had amputations caused by trauma in three
studies,98–100 and all or most amputations were caused by vascular disease (vascular disease or diabetic ulcers
in one case) in another three studies.102,104,105 One study did not report on amputation causes103 and in
another the majority had been either caused by trauma or diabetes mellitus.101 When reported, the overall
mean time since amputation at the most recent follow-up ranged from 6 months to 2.4 years. In three of
the studies,99,100,104 all participants used a prosthesis, whereas the remainder did not report this information.
Five studies98,100–102,105 reported the proportion of participants with stump pain, ranging from 19% to 91%.
Results of longitudinal studies
Results from the longitudinal studies are presented in Table 22. At the population level, PLP intensity
recorded up to 1 week post amputation ranged from 1.6 to 5.9 on a VAS scale (of 0–10). At later follow-ups,
PLP intensity in most studies was quite low with mean (or median) 0–10 VAS scores ranging from 1.8 to 3.7
at 6 months post amputation, 2.4 to 3.0 at 1 year and 2.1 to 6.0 at 2 years. Three studies98,103,104 reported
data on subcategories of pain intensity (all three reported data at, or around, 1 year post amputation). One
study98 reported that 35% of patients had a PLP of > 3 (on a 0–10 VAS). The other two studies103,104 used
mild, moderate and severe pain categories and reported that around 25% of patients had moderate pain.
There were notable differences in the proportions for mild PLP (50% and 73%) and severe PLP (25% and
0%). Two studies101,105 reported on duration or frequency of PLP episodes, both at 6 months. Richardson
et al.105 reported that around two-thirds of patients had PLP episodes lasting between 1 and 29 minutes
and 44% of patients had between two and nine episodes per day; 2% had continuous PLP. Kelle et al.101
reported much lower episode frequencies, with 56% of patients having an episode once every 10–15 days.
One study102 reported that intensity of PLP did not decrease with time but duration of PLP attacks was
significantly shorter after 6 months than after 3 months (p = 0.001).
Two studies98,100 reported that early residual limb pain (stump pain) was not correlated with PLP intensity at
later follow-ups. However, these studies did find that early PLP intensity was a predictor of chronic PLP at
6 months and 1 year.98,100 Two further studies identified an association between early and later PLP, but
the analyses did not relate to intensity of PLP: one study102 found that early PLP predicted the presence of
PLP at 6 months and another103 reported associations between PLP at 13 months and PLP during the first
month after the operation.
Three studies98,99,102 identified associations between pre-amputation pain and PLP. Hanley et al.98 found
pre-amputation pain to be a significant predictor of chronic PLP at 2 years. Similarly, Houghton et al.99 found
the level of preoperative pain in vascular amputees – but not in trauma amputees – to be correlated with
the level of PLP at periods up to and including 2 years after amputation, but there was no correlation at
5 years. This study also reported no significant difference in levels of PLP experienced by vascular and
traumatic amputees at any time. However, the Houghton et al.99 study was retrospective. In retrospective
studies, it would be very difficult for patients to provide accurate data on pre-amputation pain intensity and
PLP intensity experienced in previous years. Results from Nikolajsen et al.102 suggested that pre-amputation
pain may influence PLP early (at 3 months) but not later (at 6 months) in patients with amputations as a
result of peripheral vascular disease or diabetic ulcers. However, the results of this study were based on
using a cut-off point for ‘clinically relevant’ pain of ≥ 20 (on a 0–100 scale). Therefore, the relevance of this
study’s results to a population with moderate to severe PLP is somewhat uncertain as this population
normally has VAS score ranges of between 5 and 10 (on a 0–10 scale).
Kelle et al.101 reported a retrospective study of 101 patients not receiving medical treatment for PLP.
Results indicated that level of amputation has no impact on level of PLP. Across the longitudinal studies
identified, there were very few data published on associations between PLP and quality of life, daily
activities, anxiety or depression. The only relevant results (associations between PLP and reduced walking
distance and reduced outdoor walking) were briefly reported in a Finnish study.104
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TABLE 22 Methods and results of longitudinal epidemiology studies
Study and number
with PLP Method details
PLP intensity (mean) and prevalence by
severity
Associations between PLP and patient
characteristics, quality of life, daily activities,
anxiety or depression
Hanley et al. 200798
l Days 4–5: 38
l 6 months: 39
l 12 months: 42
l 24 months: 35
Duration of follow-up: 2 years after
amputation
Initial measurement: before amputation
(median 2 days, range 0–14 days)
Follow-up time points post amputation: days 4
and 5 (averaged), 6 months, 12 months,
24 months
Recall period: initial assessment and post
amputation = 24 hours. ≥ 6 months= average
of ratings from three times within 1-week
period
Method of PLP assessment: 0–10 numeric
rating scale
Intensity of PLP:
l Days 4–5 – 2.1
l 6 months – 2.4
l 1 year – 2.4
l 2 years – 2.1
Prevalence of PLP by severity:
l % with pain score – > 3
l Days 4–5 – 32%, 6 months – 33%,
1 year – 35%, 2 years – 30%
Pre-amputation pain intensity was a significant
predictor of PLP intensity at 2 years (p< 0.05)
Early PLP intensity was the only significant
independent predictor of PLP intensity at
6 (p < 0.01) and 12 (p< 0.001) months after
amputation; greater acute PLP (4–5 days after
amputation) was associated with higher intensity
PLP
Early residual limb pain was not a significant
independent predictor of PLP intensity at any
follow-up point
Houghton et al.
199499
l 137
Duration of retrospective follow-up: varied
by patient
Initial measurement: before amputation
Follow-up time points post amputation:
immediately after amputation, 6 months,
1 year, 2 years, 5 years and current pain at
time of survey
Recall period: between 6 months and over
5 years
Method of PLP assessment: VAS 0–10 scale
Intensity of PLP:
l Immediately after amputation – 4a
l 6 months – 3a
l 1 year – 3a
l 2 years – 2a
l 5 years – 1a
Prevalence of PLP by severity:
l NE
In vascular amputees, level of preoperative pain was
correlated with level of phantom pain: immediately
after amputation (p< 0.005), at 6 months
(p < 0.0005), 1 year (p< 0.005), 2 years (p< 0.005)
after amputation and at the time of answering the
questionnaire (p < 0.0005). No correlation at 5 years
(p = 0.19)
In trauma amputees, there was a significant
correlation between level of preoperative and level
of phantom pain only immediately after surgery
(p < 0.005)
Preoperative pain was more severe in vascular than
in trauma amputees (median 7 vs. median 2.5;
p< 0.0005)
No significant difference in levels of PLP experienced
by vascular and traumatic amputees at any time
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TABLE 22 Methods and results of longitudinal epidemiology studies (continued )
Study and number
with PLP Method details
PLP intensity (mean) and prevalence by
severity
Associations between PLP and patient
characteristics, quality of life, daily activities,
anxiety or depression
Hunter et al. 2008100
l Initial
assessment: 8
l Follow-up: 7
Duration of follow-up: mean 28.3 months
after amputation
Initial measurement: < 6 months after
amputation (mean 4.6 months)
Follow-up time points: one session
≥ 11.5 months after initial measurement
(means of 28.3 months since amputation,
24 months since initial measurement)
Recall period: within the previous week
Method of PLP assessment: VAS 0–10 scale
Intensity of PLP
l Initial – 5.9
l Follow-up – 6.0
Prevalence of PLP by severity:
l NE
Significant relationship between initial PLP intensity
and follow-up PLP intensity (p< 0.001)
Initial stump pain not correlated with PLP at follow-up
Kelle et al. 2017101
l EPP: 91
l 6 months: 45
Duration of retrospective follow-up: 6 months
after amputation
Initial measurement: ‘Early postoperative
period’
Follow-up time points: 6 months post
amputation
Recall period: unclear
Method of PLP assessment: VAS 0–10 scale
Intensity of PLP:
l EPP – 6.8
l 6 months – 3.7
Prevalence of PLP by severity:
l At EPP (n = 67 with data), 67% had
permanent PLP, 33% had PLP every day
(on and off). There were significantly
more permanent PLP patients in group I
l At 6 months (n= 45), none had
permanent or everyday PLP, 7% once
every 3 days, 16% once a week, 56%
once every 10–15 days, 22 once a month
PLP analysed by groups based on site of
amputation. Group 1, above knee and knee; group
II: below knee to ankle; group III, below ankle.
Analysis did not control for cause of amputation;
trauma was the most common cause in group I,
diabetes mellitus in group III
Significant difference between groups in PLP
intensity at EPP with highest VAS score in group I
(p = 0.02); no significant differences after 6 months
(p = 0.58)
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Study and number
with PLP Method details
PLP intensity (mean) and prevalence by
severity
Associations between PLP and patient
characteristics, quality of life, daily activities,
anxiety or depression
Nikolajsen et al.
1997102
l 1 week: 36
l 3 months: 24
l 6 months: 27
Duration of follow-up: 6 months after
amputation
Initial measurement: day before amputation
Follow-up time points post amputation:
1 week, 3 months, 6 months
Recall period: since amputation or since
previous interview
Method of PLP assessment: VAS 0–100 scale
(clinically relevant if ≥ 20mm); also MPQ
Intensity of PLP:
l 1 week – 15.5a
l 3 months – 24a
l 6 months – 22a
Prevalence of PLP by severity:
l NE
Significant association between pre-amputation VAS
pain of ≥ 20mm and PLP of ≥ 20mm during first
3 months, but not for 6-month time point (p= 0.1)
Intensity of PLP did not decrease with time but
duration of PLP attacks was significantly shorter
after 6 months than after 3 months (p= 0.001)
PLP presence at 1 week associated with PLP
presence at 6 months (p= 0.002)
Parkes 1973103
l 3–4 weeks: 39
l 13 months: 28
Duration of follow-up: 13 months after
amputation
Initial measurement: 3–4 weeks post
amputation
Follow-up time points: 13 months post
amputation
Recall period: 3–4 weeks, since amputation;
13 months, NR
Method of PLP assessment: categorical – none,
mild, moderate or severe
Intensity of PLP:
l NE
Prevalence of PLP by severity:
l At 13 months, 28/46 still had some PLP –
severe, 7 (25%); moderate, 7 (25%); mild,
14 (50%)
Association between PLP at 13 months and: illness
that lasted for more than a year before amputation
(p < 0.05), illness that persisted after operation to
produce a threat to life or the remaining limb
(p < 0.05), rigid personality (p> 0.02), compulsively
self-reliant personality (p< 0.02), PLP during first
month after operation (p < 0.05), unemployment or
retirement at 13 months (p< 0.02)
Pohjolainen 1991104
l Initial
assessment: 91
l 1 year: 66
Duration of follow-up: 1 year after amputation
Initial measurement: at prosthetic fitting
(maximum of 16 weeks after amputation)
Follow-up time points: 1 year post amputation
Recall period: NR
Method of PLP assessment: categorical – mild,
moderate, severe
Intensity of PLP:
l NE
Prevalence of PLP by severity:
l At initial assessment – mild, 73%;
moderate, 27%; severe, 0%
l 1 year – mild, 70%; moderate, 30%;
severe, 0%
Association between PLP and reduced walking
distance and reduced outdoor walking (both
p< 0.05)
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TABLE 22 Methods and results of longitudinal epidemiology studies (continued )
Study and number
with PLP Method details
PLP intensity (mean) and prevalence by
severity
Associations between PLP and patient
characteristics, quality of life, daily activities,
anxiety or depression
Richardson et al.
2006105
l First week: 54
l 6 months: 41
Duration of follow-up: 6 months after
amputation
Initial measurement: first week post
amputation
Follow-up time points: 6 months post
amputation
Recall period: NR
Method of PLP assessment: VAS 0–100;
MPQ; 0–5 scale (Present Pain Intensity)
Intensity of PLP:
l VAS score at 6 months – 27
l PPI – first week, 3.0; 6 months, 1.8
Prevalence of PLP by severity:
l At 6 months, 64% of amputees had
attacks lasting between 1 and 29 minutes,
10% for 1 hour, 12% for > 1 hour
l 44% had between 2 and 9 attacks per day,
12% had > 10 per day
NE
EPP, early postoperative period; MPQ, McGill Pain Questionnaire; NE, not evaluated; NR, not reported; PPI, present pain intensity.
a Median.
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Cross-sectional studies
Characteristics of cross-sectional studies
Table 23 shows the characteristics of the amputee populations in the cross-sectional epidemiology studies. In
most studies, questionnaires were mailed to participants or distributed by co-operating organisations. Data
were collected through face-to-face interviews in three studies106,109,110 and through telephone interviews in
one study.9 Of those studies that reported a method of selecting participants, two used random sampling10,112
and one used census sampling.109 The sample for four surveys was either self-selected or partially self-selected
(including through membership of an amputee organisation).9,111,113,116 One study107 included a mix of
participants selected through both random sampling and self-selection, and another study115 distributed
surveys through co-operating organisations.
Almost half of the studies took place in the USA,9,10,107,111–113 with three in Iran,106,109,110 one in the UK,116
and two in the rest of Europe114,115 (one study did not specify a location but appears likely to have been set
in the USA108).
TABLE 23 Characteristics of cross-sectional epidemiology studies
Study Type of data collection
Population (means unless
otherwise specified)
Ehde et al. 200010 (cohort also
reported in Hanley et al. 2006117)
Mailed survey, selection by random
number generator
Setting: USA
N included (participation rate): 255
(56%)
% with PLP: 72
Age (years): 55
% male: 8
Amputation sites: below knee, 54%;
above knee, 30%; other (hip, toes),
8%; knee disarticulation, 5%; ankle
disarticulation, 3%
Amputation cause: trauma, 53%;
vascular disease, 20%; infection,
23%; gangrene, 21%; diabetes
mellitus, 13%; congenital problem,
2%; tumour, 5%; other, 19%
(multiple answers allowed)
Time since amputation (years): 14.2
% with prosthesis: 83
Comorbidities: 74% stump pain, 52%
back pain, 43% pain in other leg/foot
Ephraim et al. 20059 Telephone interviews, sample
stratified by amputation aetiology
(from those who contacted Amputee
Coalition of America)
Setting: USA
N included (participation rate): 914
(67%)
% with PLP: 80
Age (years): 50
% male: 60
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TABLE 23 Characteristics of cross-sectional epidemiology studies (continued )
Study Type of data collection
Population (means unless
otherwise specified)
Amputation sites: below knee, 41%;
above knee, 38%; bilateral lower
limb, 10%; above elbow, 5%; below
elbow, 5%; bilateral upper limb, 1%
Amputation cause: peripheral vascular
disease, 37%; trauma, 39%; cancer,
24%
Time since amputation (years): 4a
(0–66 range)
% with prosthesis: 80
Comorbidities: 68% stump pain, 62%
back pain
Hirsh et al. 2010108 Mailed survey Setting: NR (USA?)
N included (participation rate): 335
(56.2%)
% with PLP: 83
Age (years): 59
% male: 72
Amputation sites: lower limb, 99%;
upper limb, 5% (11 participants had
both)
Amputation cause: trauma, 78%;
other causes NR
Time since amputation (years): 19
% with prosthesis: NR
Comorbidities: 64% stump pain
Modirian et al. 2009106 Interviews in a medical setting Setting: Iran
N included (participation rate): 103
(74%)
% with PLP: 54 (% of limbs)
Age (years): 38
% male: 99
Amputation sites: bilateral. Finger/
wrist, 52%; at elbow, 40%; above
elbow, 8%
Amputation cause: all war injuries
Time since amputation (years): 17.1
% with prosthesis: NR
Comorbidities: 40% overweight,
8% obese
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TABLE 23 Characteristics of cross-sectional epidemiology studies (continued )
Study Type of data collection
Population (means unless
otherwise specified)
Molton et al. 2007107 (some overlap of
patients with Ehde et al. 200010)
Mailed survey, selection by random
number generator and some self-
selecting – responses to flyers/
advertisements
Setting: USA
N included (participation rate): 375
(51%)
% with PLP: 100
Age (years): 54
% male: 67
Amputation sites: below knee, 55%
Amputation cause: injury, 52%;
vascular disease, 24%; infection, 24%
Time since amputation (years): 11.0
% with prosthesis: NR
Comorbidities: NR
Rahimi et al. 2012109 Face-to-face interviews, census
sampling for selection
Setting: Iran
N included (participation rate): 335
(58%)
% with PLP: 67
Age (years): 42
% male: 97
Amputation sites: bilateral. 38%
below knee, 22% above knee, 34%
above and below knee, 6% NR
Amputation cause: all war injuries
Time since amputation (years): 20
% with prosthesis: 80
Comorbidities: 61% vertebral column
pain
Rayegani et al. 2010110 Face-to-face interviews by medical
professional
Setting: Iran
N included (participation rate): 335
(84%)
% with PLP: 64
Age (years): 42
% male: 98
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TABLE 23 Characteristics of cross-sectional epidemiology studies (continued )
Study Type of data collection
Population (means unless
otherwise specified)
Amputation sites: bilateral. By limb:
below knee, 53%; above knee, 36%;
knee disarticulation, 7%; other, 4%
Amputation cause: all war injuries
Time since amputation (years): NR
% with prosthesis: 79
Comorbidities: 53% low back pain,
22% neck pain, 9% thoracic spine
pain
Sherman and Sherman 1983111 Mailed survey, partially self-selected
(members of society of veteran
amputees)
Setting: USA
N included (participation rate): 764
(61%)
% with PLP: 85
Age (years) 51
% male: NR
Amputation sites: lower limb, 82%;
upper limb, 14%; bilateral upper and
lower limbs, 4%
Amputation cause: all related to
military service. Combat related, 85%;
accidents, 6%; other causes NR
Time since amputation (years): 28.2
% with prosthesis: > 90
Comorbidities: 58% stump pain
Sherman and Sherman 1985113 Mailed survey, self-selecting sample in
response to requests in newspapers
Setting: USA
N included (participation rate): 436
(85%)
% with PLP: 100
Age (years): 59
% male: 89
Amputation sites: NR
Amputation cause: all unrelated to
military service. Accidents, 50%;
disease, 46%
Time since amputation (years): 14
% with prosthesis: NR
Comorbidities: 58% stump pain
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TABLE 23 Characteristics of cross-sectional epidemiology studies (continued )
Study Type of data collection
Population (means unless
otherwise specified)
Sherman et al. 1984112 Mailed survey, random selection Setting: USA
N included (participation rate): 2694
(55%)
% with PLP: 78
Age (years): 53
% male: 100
Amputation sites: NR
Amputation cause: all related to
military service. Direct combat injuries,
42%; combat-associated problems,
34%; accidents, 18%; disease, 6%
Time since amputation (years): 26.9
% with prosthesis: NR
Comorbidities: 62% stump pain
Solonen 1962114 Sample of first 1000 completed of
4000 distributed surveys
Setting: Finland
N included (participation rate): 1000
(N/A)
% with PLP: 68
Age (years): 42
% male: 100
Amputation sites: below knee, 43%;
above knee, 27%; above elbow,
16%; below elbow, 10%; bilateral,
3%; foot, 1%
Amputation cause: all war injuries
Time since amputation (years): 14
% with prosthesis: 99
Comorbidities: 42% stump pain
Streit et al. 2015115 Surveys distributed by co-operating
organisations
Setting: Germany
N included (participation rate): 122
(NR for bilateral amputees)
% with PLP: 74% (lifetime), 56% of
limbs (last 3 months)
Age (years): 65
% male: 76
Amputation sites: bilateral. Lower
limb, 73%; upper limb, 13%; upper
and lower limb, 14%
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The number of participants ranged from 103 to 2694, with most studies including < 1000 participants.
There was some overlap in the cohorts of patients included in two of the studies,10,107 although it is not
reported how many patients were included in both of them. The proportion of participants with PLP
ranged from 52% to 82%, except for two studies107,113 in which only participants with PLP were included.
Mean ages ranged from 38 to 72 years. In all studies, most participants were male (when reported).
Four studies106,109,110,115 only included participants with bilateral amputations. One study106 included only
upper-limb amputees and two studies112,113 did not report on amputation site. The remaining studies
included either only lower-limb amputees or cohorts in which most patients were lower-limb amputees.
Seven studies106,109–112,114,116 were of military veterans or those injured at war. The remainder of studies
included participants with different amputation causes, the most common being trauma. Time since
amputation (mean or median) ranged from 4 to 50 years. Prosthesis use was high in those studies that
reported it (79% to 99%). In studies that reported on comorbidities, 42% to 75% of participants reported
stump pain and 52% to 62% of participants reported back pain.
TABLE 23 Characteristics of cross-sectional epidemiology studies (continued )
Study Type of data collection
Population (means unless
otherwise specified)
Amputation cause: by limb – trauma,
66%; vascular disease, 24%;
infection, 7%; tumour, 0.4%; other,
7% (multiple answers allowed)
Time since amputation (years): 31.2
% with prosthesis: NR
Comorbidities: 60% (of limbs) stump
pain
Wartan et al. 1997116 Mailed survey to the British Limbless
Ex-Servicemen’s Association (now
known as Blesma, The Limbless
Veterans)
Selection by random number
generator
Setting: UK
N included (participation rate): 526
(89%)
% with PLP: 62% (lifetime), 52%
(current)
Age (years): 73a
% male: 100
Amputation sites: below knee, 48%;
above knee, 42%; above elbow,
10%; below elbow, 9% (includes
some amputees with amputations at
more than one site)
Amputation cause: all trauma. Active
military service, 89%
Time since amputation (years): 50a
% with prosthesis: 96
Comorbidities: 57% stump pain
N, number of amputees; N/A, not applicable; NR, not reported.
a Median.
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Results of cross-sectional studies
The results of the cross-sectional studies are reported in Table 24. Six of the cross-sectional studies9,10,107,108,113,115
reported population mean VAS scores for PLP. The range of means was quite narrow, being between 4.6
and 6.1 (out of 10) and notably higher than was seen in the longitudinal studies (range 2.4 to 3 at 1 year
post amputation).
Seven studies9,10,106,109,110,112,114 reported data on categories of pain intensity. The proportions of patients
with ‘severe’ PLP – usually defined as being between scores of 7 and 10 on a VAS – ranged between 13%
and 39% across five studies: 30%,10 39%,9 38%,109 13%110 and 29%.112 The proportions of patients with
‘moderate’ PLP (between 5 and 6 on a VAS) ranged between 23% and 29% across three studies.9,110,112
The proportions of patients with ‘mild’ PLP (between 0 or 1 and 4 on a VAS) ranged between 35% and
64% across three studies.9,110,112 Modirian et al.106 reported the proportion with ‘discomforting’ PLP as
26%, the proportion with ‘distressing’ PLP as 35% and the proportion with ‘excruciating’ PLP as 38%.
Two studies provided data on the ‘bothersomeness’ of PLP.9,10 The study by Ephraim et al.9 reported that
the pain was not bothersome for 19% of participants, the pain was somewhat bothersome for 54% of
participants and the pain was extremely bothersome for 27% of participants. The Ehde et al.10 study
reported that 10% of participants found PLP to be not at all bothersome, 42% of participants found PLP
to be mildly bothersome, 16% of participants found PLP to be moderately bothersome and 32% of
participants found PLP to be severely bothersome.
Only one study (Ehde et al.10) reported data on how pain intensity related to pain-related disability using
the Chronic Pain Grade Classification: 47% of patients had low pain intensity and low disability, 28% of
patients had high pain intensity and low disability, 9% of patients had high disability that was moderately
limiting and 14% of patients had high disability that was severely limiting. In 1962, Solonen114 reported a
3% rate for patients with severe, persistently incapacitating PLP.
Six studies10,109,110,112,113,116 reported on frequency of PLP attacks, although the categorisation of frequencies
varied across studies. Two related studies by Sherman et al.112 and Sherman and Sherman113 reported that
just under half of patients have PLP attacks on between 1 and 5 days every month and around one-third
have PLP attacks on > 20 days per month. One study116 reported that 40% of patients had PLP a few times
per month and that 28% of patients had continuous PLP. Another study10 reported that half of patients
had one or fewer episodes of PLP per week. Rahimi et al.109 reported that 21% of patients said that they
always or usually suffered with PLP, and Rayegani et al.110 reported that 5% of patients ‘always’ have PLP,
13% ‘often’ have PLP, 37% ‘sometimes’ have PLP and 44% ‘rarely’ have PLP.
Two related studies112,113 reported on duration of PLP attacks. Around one-third of patients had attacks
lasting ‘seconds’, and around one-third of patients had attacks lasting ‘hours’. Around 10–20% of patients
had continuous PLP; although respondents could answer this duration question with free text, ‘minutes’
was not listed as an example option.
Four studies9,107–109 reported on associations relating to populations with chronic PLP. The study by Molton
et al.107 concluded that, in a population with lower extremity amputations, the relationship between pain
intensity and pain-related interference with daily living was stronger in younger adults than in older adults
and that this was driven by greater time since injury in older adults. The study (which undertook analyses
that controlled for variables, such as type of injury and baseline pain severity) also found that neither reason
for amputation nor amputation location was significantly associated with PLP severity or interference with
daily living (except for a subgroup of gangrene amputation patients). A larger study9 found no association
for time since amputation when comparing severe PLP with mild PLP, although the time since amputation
(median of 4 years) was notably shorter than in the Molton et al.107 study (mean of 11 years). There were
also no significant associations for sex, age or aetiology of amputation. Severe PLP was significantly
associated with depressed mood and lower-limb amputation. This study also reported that extremely
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TABLE 24 Methods and results of large cross-sectional epidemiology studies
Study Amputees with PLP Method details Intensity of PLP (mean)
Results: PLP prevalence by severity and associations
between PLP and patient characteristics, quality of life,
daily activities, anxiety or depression
Modirian et al. 2009106 Unclear, but 112 limbs Recall period: NR
Method of PLP assessment:
categorical
NE Prevalence of PLP by severity: by limb (n= 112) – mild, 1%;
discomforting, 26%; distressing, 35%; excruciating, 38%
Associations: NE
Molton 2007107 375 Recall period: 3 months
Method of PLP assessment:
0–10 scale
4.6 Prevalence of PLP by severity: NR
Associations: the relationship between PLP severity and
pain-related interference with daily living was moderated by age
(p< 0.05). Analysis of age group differences in pain-related
interference by pain level showed a large effect when pain was
moderate/severe, but not when mild/moderate; younger adults
had much higher pain-related interference (p < 0.001) than older
adults. Time since amputation was a significant predictor of pain
interference above and beyond chronological age. Neither reason
for amputation nor amputation location was significantly
associated with PLP severity or interference, except for gangrene
amputation patients (n = 78) reporting greater PLP intensity than
patients with other causes of amputation; p < 0.05
Note that some patients in this study overlap with the Ehde et al.
200010 cohort described below
Ehde et al. 200010 (cohort
also reported in Hanley
et al. 2006117)
183 Recall period: 3 months
Method of PLP assessment:
0–10 scale
5.1
Half reported ≤ 1 episode
per week
Prevalence of PLP by severity: 30% reported mean PLP of severe
intensity (i.e. between 7 and 10). Not at all bothersome, 10%;
mildly bothersome (1–4 on scale), 42%; moderately bothersome
(5–6), 16%; severely bothersome (7–10), 32%. Chronic pain
grade classification: pain free, 2%; grade I (low disability, low
pain intensity), 47%; grade II (low disability, high pain intensity),
28%; grade III (high disability – moderately limiting), 9%;
grade IV (high disability – severely limiting), 14%
Associations: NE
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Study Amputees with PLP Method details Intensity of PLP (mean)
Results: PLP prevalence by severity and associations
between PLP and patient characteristics, quality of life,
daily activities, anxiety or depression
Ephraim et al. 20059 727 Recall period: 4 weeks
Method of PLP assessment:
1–10 scale
5.5 Prevalence of PLP by severity: mild (1–4 on scale), 35%; moderate
(5–6), 26%; severe (7–10), 39%. Pain not bothersome, 19%;
somewhat bothersome, 54%; extremely bothersome, 27%
Associations: severe (vs. mild) PLP significantly associated (p< 0.05)
with depressed mood score of ≥ 10 on CES-D scale and lower-limb
amputation, but no associations for time since amputation, sex,
age and aetiology of amputation. Extremely bothersome (vs. not
bothersome) PLP significantly associated (p< 0.05) with younger
age (less likely in 55- to 64-year age group than in 18- to 44-year
age group), ≥ 2 comorbid conditions, CES-D score of ≥ 10 and not
wearing a prosthesis (vs. ≥ 9 hours of daily wear). Somewhat
bothersome (vs. not bothersome) PLP significantly associated
(p< 0.05) with CES-D score of ≥ 10
Hirsh et al. 2010108 279 Recall period: 1 week
Method of PLP assessment:
0–10 scale
5.3 Prevalence of PLP by severity: NR
Associations: no difference between the sexes found for the
intensity or presence of PLP
Rahimi et al. 2012109 223 Recall period: NR
Method of PLP assessment:
categorical
NE Prevalence of PLP by severity: severe, 38%; 21% said they always
or usually suffered with PLP
Associations: significant relationship (p< 0.05) between severe
phantom pain (vs. not severe) and lower scores on SF-36 domains
of physical functioning, general health and physical component
scale
Rayegani et al. 2010110 214 Recall period: 4 weeks
Method of PLP assessment:
0–10 scale
NR Prevalence of PLP by severity: by limb (n= 426) – very mild (1–2
on scale), 40%; mild (3–4), 24%; moderate (5–6), 23%; severe
(7–10), 13%. 5% ‘always’ have PLP, 13% ‘often’ (> 8 hours/day),
37% ‘sometimes’, 44% ‘rarely’
Associations: NE
Sherman and Sherman
1983111
648 Recall period: NR
Method of PLP assessment:
0–100 scale
‘Worst’: 68.7
‘Least usual’: 18.0
Prevalence of PLP by severity: NE
Associations: NE (comparisons only for PLP vs. no PLP populations)
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TABLE 24 Methods and results of large cross-sectional epidemiology studies (continued )
Study Amputees with PLP Method details Intensity of PLP (mean)
Results: PLP prevalence by severity and associations
between PLP and patient characteristics, quality of life,
daily activities, anxiety or depression
Sherman et al. 1984112 2101 Recall period: not specified
on questionnaire
Method of PLP assessment:
0–10 scale
Usual: 5.3
Worst: 7.7
Least: 2.9
Prevalence of PLP by severity: usual pain intensity rating –
0= 1.4%, 1= 6.2%, 2= 10.9%, 3= 12.7%, 4 = 10.5%,
5= 19.1%, 6= 9.9%, 7= 7.3%, 8= 10.5%, 9 = 2.9%,
10= 8.4%. Days per month of PLP – 27% over 20 days, 10%
11–20 days, 14% 6–10 days, 35% 2–5 day, 14% 1 day. Hours
per day of PLP – 27% > 15 hours, 7% 11–15 hours, 14% 6–10
hours, 32% 2–5 hours, 20% ≤ 1 hour. Length of episodes –
‘seconds’, 38%; ‘hours’, 37%; ‘days’, 11%; ‘months’, 2%;
‘continuous’, 12%
Associations: NE (comparisons only for PLP vs. no PLP populations)
Sherman and Sherman
1985113
436 Recall period: NR
Method of PLP assessment:
0–10 scale
Mean: 5.0
Worst: 7.4
Least: 2.4
Prevalence of PLP by severity: days per month of PLP – 40% over
20 days, 7% 11–20 days, 8% 6–10 days, 31% 2–5 day, 13%
1 day, 1% < 1 day. Hours per day of PLP – 35% > 15 hours, 7%
11–15 hours, 11% 6–10 hours, 29% 2–5 hours, 18% ≤ 1 hour.
Length of episodes – ‘seconds’, 37%; ‘hours’, 33%; ‘days’, 8%;
‘months’, 1%; ‘continuous’, 20%
Associations: NE
Solonen 1962114 678 Recall period: NR
Method of PLP assessment:
categorical
NE Prevalence of PLP by severity: 3% had severe, persistently
incapacitating PLP
Associations: NE
Streit et al. 2015115 68 Recall period: intensity –
4 weeks
Method of PLP assessment:
0–10 scale
6.14 Prevalence of PLP by severity: NE
Associations: only reported for a broader population (of around
90 patients) with a lifetime history of PLP – this included patients
in remission (i.e. no PLP in previous 3 months)
Wartan et al. 1997116 144 (patients with stable,
chronic PLP)
Recall period: not specified
on questionnaire
Method of PLP assessment:
0–10 scale
NR for chronic population Prevalence of PLP by severity: 15 (10%) had a few PLP attacks per
year, 58 (40%) had PLP a few times per month, 27 (19%) had a
few PLP attacks per day, 5 (3%) had a few attacks per hour and
39 (28%) reported that PLP was always present
Associations: NE (comparisons only for any PLP vs. no PLP
populations)
CES-D, Centre for Epidemiologic Studies Depression scale (range 0–30); NE, not evaluated; NR, not reported.
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bothersome PLP (vs. not bothersome) was significantly associated with younger age, depressed mood,
having comorbidities and not wearing a prosthesis.
In the remaining two studies, which looked at associations with PLP, one109 identified a significant relationship
between severe PLP (vs. not severe) and lower scores on SF-36 domains of physical functioning, general
health and physical component scale, and one108 reported no difference between the sexes for the intensity
or presence of PLP.
Summary
The evidence on prognostic factors for the development of chronic PLP in patients with PLP following
amputation has important limitations. Although the literature searches identified numerous epidemiological
studies that reported results for chronic PLP cohorts, fewer than one-third of the studies had a prospective
design. Moreover, only one of the prospective studies had a sample size of > 100 (so some results may have
been prone to chance effects), and follow-up durations were generally limited to between 6 months and
2 years. Mean VAS scores indicated that most patients had quite mild PLP. The longitudinal study results
suggested that both pre-amputation pain and early PLP intensity are good predictors of chronic PLP up to
2 years after amputation. Neither level of amputation nor early stump pain seem to be correlated with PLP
intensity at later follow-ups.
Most of the epidemiology studies had a cross-sectional design, in which each patient’s data were collected
at a single point in time. Results from such studies often cannot establish the direction and causality of any
associations found. For example, the reported association between chronic severe PLP and depression
might imply that severe PLP is a risk factor for developing depression (implying that treatment for severe
PLP is paramount). Alternatively, it may be that existing depression is a risk factor for severe PLP (implying
that treatment for depression is more urgent). Longitudinal cohort studies could answer such questions but
none of the longitudinal studies in our review addressed outcomes, such as depression, anxiety and quality
of life. Although many of the cross-sectional studies had large sample sizes, many of them also had
participation rates of between around 50% and 70%. Therefore, it is possible that these studies’ results
were subject to non-response bias, which might limit their generalisibility to the broader chronic PLP
population.
Nevertheless, cross-sectional studies may be useful for estimating disease prevalence.118 Results suggest
that the proportion of patients with chronic PLP that is severe lies between around 30% and 40%,
whereas the proportion of patients with moderate chronic PLP is around 25%. From the studies reporting
data on how chronic PLP affects patients’ daily lives, it appears that around 25% of chronic PLP patients
find their PLP to be either moderately or severely limiting or bothersome. Considerable variation was
reported across studies regarding the frequency and duration of PLP attacks; for example, estimates of the
proportion of patients with continuous PLP range from around 2% to 20%.
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Chapter 3 Survey of NHS practice
The aims of the survey were (1) to provide the views of clinicians who deliver neurostimulation therapiesregarding which treatments are being used to treat chronic PLP in NHS patients and how effective
those treatments are perceived to be, and (2) to elicit opinions regarding future research studies.
Methods
A questionnaire was designed and distributed using Qualtrics® software (May 2017 version; Qualtrics®,
Provo, UT, USA). The questionnaire was first piloted by clinical members of the review team. We distributed
the survey via the e-mail lists of the British Society for Stereotactic and Functional Neurosurgery and the
Neuromodulation Society of the United Kingdom and Ireland. The survey was distributed between September
and November 2017. Responses were made anonymously, although responders had the option of providing
an e-mail address, should they wish to be notified about the publication of this report. It was not possible to
calculate an overall response rate as we did not have direct access to the e-mail distribution lists.
The survey asked questions about the frequency of use of specific treatments and their perceived effectiveness.
Questions were also asked about the viability of future research studies and treatment preferences in these
studies. The full questionnaire content can be found in Report Supplementary Material 3. No imputations were
used for missing data in partially completed questionnaires. Data were assumed to be missing at random,
with the most probable reasons for missing data assumed to be lack of time (e.g. the questionnaire had been
started but the respondent did not have time to complete it) and a lack of information or knowledge (to hand)
to complete the survey. Results were analysed and narratively presented with accompanying tables when
appropriate. The unit of analysis was at the individual level (rather than at the unit level) for all questions.
Results
A total of 37 questionnaires were received from 30 different hospitals. Thirty-four questionnaires (92%)
were fully completed and three (8%) were partially completed. Key summary results relating to each
question are presented in the following sections.
Respondent characteristics
Thirty-four questionnaires were received from respondents in England, and one questionnaire each was
received from respondents in Wales, Northern Ireland and the Republic of Ireland. Twenty-five responses
(68%) were from pain management clinics, 11 were from neurosurgery units and one (3%) response was
from a rehabilitation unit. Responders were either pain physicians (23 responders, 62%), neurosurgeons
(11 responders, 30%), anaesthetists (two responders, 5%) or rehabilitation physicians (one response, 3%).
Questions and responses
Please consider the list below of 12 types of treatment. How frequently would you
estimate that each of them is used in your unit in patients who have chronic phantom
limb pain?
The responses to this question are summarised in Table 25, which provides both overall results and results
split by the main clinician subgroups: pain physicians and neurosurgeons.
The results indicate a very high use of pharmacological treatments in the chronic PLP population.
Cognitive–behavioural therapy (CBT) and mirror therapy or graded motor imagery are frequently used
interventions, but opinions on the frequency of use of acupuncture and TENS were much more variable.
Relatively few patients receive myoelectric prostheses, DREZ and transcranial stimulation therapies. Of the
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TABLE 25 Clinician estimates of prevalence of intervention use in patients with chronic PLP
Intervention
Prevalence, n (%)
Always
used
Usually
used
Sometimes
used
Rarely
used
Never
used
Do not
know
Pharmacologics
Full sample (N= 35) 24 (69) 8 (23) 0 2 (6) 1 (3) 0
Pain physicians (N = 22) 16 (73) 4 (18) 0 2 (9) 0 0
Neurosurgeons (N= 10) 7 (70) 2 (20) 0 0 1 (10) 0
TENS
Full sample (N= 37) 4 (11) 2 (5) 17 (46) 10 (27) 3 (8) 1 (3)
Pain physicians (N = 23) 2 (9) 1 (4) 11 (48) 8 (35) 1 (4) 0
Neurosurgeons (N= 11) 2 (18) 1 (9) 4 (36) 2 (18) 1 (9) 1 (9)
Acupuncture
Full sample (N= 37) 1 (3) 6 (16) 10 (27) 12 (32) 7 (19) 1 (3)
Pain physicians (N = 23) 0 2 (9) 8 (35) 10 (43) 3 (13) 0
Neurosurgeons (N= 11) 1 (9) 4 (36) 0 2 (18) 3 (27) 1 (9)
Mirror therapy/graded motor imagery
Full sample (N= 37) 5 (14) 13 (35) 8 (22) 7 (19) 2 (5) 2 (5)
Pain physicians (N = 23) 4 (17) 9 (39) 5 (22) 5 (22) 0 0
Neurosurgeons (N= 11) 1 (9) 3 (27) 1 (9) 2 (18) 2 (18) 2 (18)
CBT
Full sample (N= 37) 13 (35) 10 (27) 7 (19) 1 (3) 5 (14) 1 (3)
Pain physicians (N = 23) 8 (35) 8 (35) 4 (17) 1 (4) 2 (9) 0
Neurosurgeons (N= 11) 5 (45) 2 (18) 1 (9) 0 2 (18) 1 (9)
Myoelectric prosthesis
Full sample (N= 37) 0 2 (5) 5 (14) 4 (11) 22 (59) 4 (11)
Pain physicians (N = 23) 0 0 3 (13) 4 (17) 15 (65) 1 (4)
Neurosurgeons (N= 11) 0 2 (18) 1 (9) 0 5 (45) 3 (27)
Spinal cord stimulation
Full sample (N= 37) 1 (3) 7 (19) 21 (57) 1 (3) 7 (19) 0
Pain physicians (N = 23) 0 6 (26) 11 (48) 1 (4) 5 (22) 0
Neurosurgeons (N= 11) 1 (9) 1 (9) 8 (73) 0 1 (9) 0
Dorsal root ganglion stimulation
Full sample (N= 36) 2 (6) 11 (31) 11 (31) 2 (6) 7 (19) 3 (8)
Pain physicians (N = 23) 1 (4) 7 (30) 9 (39) 1 (4) 5 (22) 0
Neurosurgeons (N= 11) 1 (9) 4 (36) 1 (9) 1 (9) 2 (18) 2 (18)
Deep brain stimulation
Full sample (N= 37) 0 2 (5) 6 (16) 4 (11) 23 (62) 2 (5)
Pain physicians (N = 23) 0 0 2 (9) 3 (13) 16 (70) 2 (9)
Neurosurgeons (N= 11) 0 2 (18) 4 (36) 1 (9) 4 (36) 0
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invasive neurostimulation therapies, SCS seems to be the most prevalent, with around three-quarters of
both pain physicians and neurosurgeons indicating that their patients usually or sometimes use SCS. DRG
stimulation is also frequently used (although a little less so than SCS). The prevalence of the use of DBS
and MCS was quite low, as would be expected given the current lack of funding for these treatments.
The use of DBS was higher in patients attending neurosurgery units than in patients attending pain
management clinics.
Based on your experience of patients with chronic phantom limb pain, how do you
rate the effectiveness – in terms of pain relief – of the same 12 types of treatment
listed below?
The responses to this question are summarised in Table 26.
Most clinicians considered pharmacological treatments and CBT to be at least sometimes effective for
alleviating pain in chronic PLP patients. TENS was not thought to be very effective by most clinicians, but
around two-thirds of neurosurgeons considered acupuncture to be sometimes effective. Pain physicians
considered mirror therapy and graded motor imagery interventions to be more frequently effective than
did neurosurgeons. A large majority of responders considered both SCS and DRG stimulation to be either
mostly effective or sometimes effective for reducing PLP. Neurosurgeons were split in their opinions on
how frequently DBS is effective: one-third thought that it was mostly effective, one-third thought that it
was sometimes effective and one-third thought that it was rarely effective. A majority of neurosurgeons
considered MCS to be rarely effective. Most pain physicians selected ‘Don’t know’ when asked about how
frequently DBS and MCS were effective.
TABLE 25 Clinician estimates of prevalence of intervention use in patients with chronic PLP (continued )
Intervention
Prevalence, n (%)
Always
used
Usually
used
Sometimes
used
Rarely
used
Never
used
Do not
know
Motor cortex stimulation
Full sample (N= 37) 1 (3) 1 (3) 1 (3) 3 (8) 29 (78) 2 (5)
Pain physicians (N = 23) 0 1 (4) 0 1 (4) 19 (83) 2 (9)
Neurosurgeons (N= 11) 1 (9) 0 1 (9) 2 (18) 7 (64) 0
Transcranial magnetic/current stimulation
Full sample (N= 37) 0 2 (5) 2 (5) 1 (3) 27 (73) 5 (14)
Pain physicians (N = 23) 0 1 (4) 0 1 (4) 17 (74) 4 (17)
Neurosurgeons (N= 11) 0 1 (9) 2 (18) 0 7 (64) 1 (9)
DREZ
Full sample (N= 37) 0 2 (5) 0 5 (14) 27 (73) 3 (8)
Pain physicians (N = 23) 0 2 (9) 0 4 (17) 15 (65) 2 (9)
Neurosurgeons (N= 11) 0 0 0 1 (9) 9 (82) 1 (9)
CBT, cognitive–behavioural therapy.
Note
Percentages are of the response total for each intervention.
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TABLE 26 Clinician opinions on intervention effectiveness for pain relief in chronic PLP patients
Intervention
Clinician opinions, n (%)
Mostly effective Sometimes effective Rarely effective Do not know
Pharmacologics
Full sample (N= 34) 5 (15) 21 (62) 7 (21) 1 (3)
Pain physicians (N = 22) 4 (18) 13 (59) 5 (23) 0
Neurosurgeons (N= 9) 0 6 (67) 2 (22) 1 (11)
TENS
Full sample (N= 34) 0 10 (29) 20 (59) 4 (12)
Pain physicians (N = 22) 0 6 (27) 13 (59) 3 (14)
Neurosurgeons (N= 9) 0 3 (33) 5 (56) 1 (11)
Acupuncture
Full sample (N= 34) 0 11 (32) 21 (62) 2 (6)
Pain physicians (N = 22) 0 3 (14) 17 (77) 2 (9)
Neurosurgeons (N= 9) 0 6 (67) 3 (33) 0
Mirror therapy/graded motor imagery
Full sample (N= 34) 3 (9) 19 (56) 11 (32) 1 (3)
Pain physicians (N = 22) 3 (14) 13 (59) 6 (27) 0
Neurosurgeons (N= 9) 0 3 (33) 5 (56) 1 (11)
CBT
Full sample (N= 34) 3 (9) 21 (62) 9 (26) 1 (3)
Pain physicians (N = 22) 3 (14) 12 (55) 7 (32) 0
Neurosurgeons (N= 9) 0 7 (78) 2 (22) 0
Myoelectric prosthesis
Full sample (N= 33) 0 8 (24) 1 (3) 24 (73)
Pain physicians (N = 22) 0 5 (23) 0 17 (77)
Neurosurgeons (N= 8) 0 2 (25) 1 (13) 5 (63)
Spinal cord stimulation
Full sample (N= 33) 3 (9) 23 (70) 1 (3) 6 (18)
Pain physicians (N = 22) 1 (5) 16 (73) 0 5 (23)
Neurosurgeons (N= 8) 2 (25) 5 (63) 1 (13) 0
Dorsal root ganglion stimulation
Full sample (N= 34) 6 (18) 19 (56) 1 (3) 8 (24)
Pain physicians (N = 22) 3 (14) 14 (64) 1 (5) 4 (18)
Neurosurgeons (N= 9) 3 (33) 4 (44) 0 2 (22)
Deep brain stimulation
Full sample (N= 34) 3 (9) 5 (15) 5 (15) 21 (62)
Pain physicians (N = 22) 0 2 (9) 2 (9) 18 (82)
Neurosurgeons (N= 9) 3 (33) 3 (33) 3 (33) 0
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Have you ever administered any of the following treatments to patients with phantom
limb pain?
The responses to this question are summarised in Table 27. This illustrates the broader experience of
neurosurgeons in delivering a range of neurostimulation treatments.
Regarding a future research study, do you think that a randomised trial design can be
successfully used to study neuromodulation therapies for chronic phantom limb pain?
(Only responders who indicated that they had administered one of the neuromodulation
therapies listed in the previous question were asked this question)
From 24 responses, 19 responders stated ‘Yes’, three stated ‘No’ and two stated ‘Don’t know’.
It would be helpful if you could say why a randomised trial design might not be viable.
If you have any thoughts on alternative study designs you think might be more
appropriate, and thoughts on which neuromodulation treatments you would like to see
studied, please also state them here
Of the three responders who foresaw difficulties with conducting a RCT, two mentioned problems in
recruiting enough participants. One of these responders added that ‘heterogeneity’ and the ‘nature of pain
research’ would be an issue but did not elaborate further. One responder said that double blinding would
be difficult.
Please select which neuromodulation therapy or therapies you would like to see studied
in a randomised trial (Only responders who said that they thought that a randomised
controlled trial design could be used to study neuromodulation therapies for chronic PLP
were asked this question)
The responses to this question are summarised in Table 28. Pain physicians would most like to see SCS and
DRG stimulation studied in a RCT. Neurosurgeons would most like to see DRG stimulation and DBS studied
in a RCT.
TABLE 26 Clinician opinions on intervention effectiveness for pain relief in chronic PLP patients (continued )
Intervention
Clinician opinions, n (%)
Mostly effective Sometimes effective Rarely effective Do not know
Motor cortex stimulation
Full sample (N= 34) 1 (3) 2 (6) 6 (18) 25 (74)
Pain physicians (N = 22) 0 0 2 (9) 20 (91)
Neurosurgeons (N= 9) 1 (11) 2 (22) 4 (44) 2 (22)
Transcranial magnetic/current stimulation
Full sample (N= 34) 0 4 (12) 3 (9) 27 (79)
Pain physicians (N = 22) 0 0 2 (9) 20 (91)
Neurosurgeons (N= 9) 0 4 (44) 1 (11) 4 (44)
DREZ
Full sample (N= 33) 0 3 (9) 4 (12) 26 (79)
Pain physicians (N = 22) 0 2 (9) 3 (14) 17 (77)
Neurosurgeons (N= 9) 0 1 (11) 1 (11) 7 (78)
CBT, cognitive–behavioural therapy.
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TABLE 27 Numbers of clinicians who have administered neurostimulation therapies
Intervention
Clinicians who have/have not administered neurostimulation therapies, n (%)
Yes No
Spinal cord stimulation
Full sample (N= 34) 23 (68) 11 (32)
Pain physicians (N = 22) 14 (64) 8 (36)
Neurosurgeons (N= 9) 8 (89) 1 (11)
Dorsal root ganglion stimulation
Full sample (N= 34) 17 (50) 17 (50)
Pain physicians (N = 22) 11 (50) 11 (50)
Neurosurgeons (N= 9) 6 (67) 3 (33)
Deep brain stimulation
Full sample (N= 34) 8 (24) 26 (76)
Pain physicians (N = 22) 0 22 (100)
Neurosurgeons (N= 9) 8 (89) 1 (11)
Motor cortex stimulation
Full sample (N= 34) 3 (9) 31 (91)
Pain physicians (N = 22) 0 22 (100)
Neurosurgeons (N= 9) 3 (33) 6 (67)
Transcranial magnetic/current stimulation
Full sample (N= 34) 2 (6) 32 (94)
Pain physicians (N = 22) 0 22 (100)
Neurosurgeons (N= 9) 2 (22) 7 (78)
TABLE 28 Clinician intervention preferences for a future randomised trial
Intervention
Counts, n (% of total counts)
All responses Pain physicians Neurosurgeons
SCS 15 (31) 10 (40) 4 (19)
Dorsal root ganglion stimulation 18 (38) 10 (40) 7 (33)
DBS 8 (17) 2 (8) 6 (29)
MCS 3 (6) 1 (4) 2 (10)
Transcranial magnetic/current stimulation 4 (8) 2 (8) 2 (10)
Total 48 (100) 25 (100) 21 (100)
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Are you aware of any summary data on the effectiveness or safety of neuromodulation
therapies for phantom limb pain that we are unlikely to have identified in our searches
of literature databases (e.g. unpublished data and very recent conference abstracts)?
(Only responders who had administered a neuromodulation treatment were asked
this question)
Two responders said ‘Yes’: one mentioned a conference abstract (which we had identified in our previous
searches) and one provided their e-mail address but did not respond when details were requested. Sixteen
responders replied ‘No’ and six stated ‘Don’t know’.
Summary of survey findings
The survey results indicated that SCS seems to be the most frequently used neuromodulation therapy in
the NHS: around three-quarters of both pain physicians and neurosurgeons indicated that their patients
usually or sometimes use SCS. DRG stimulation is also frequently used. The prevalence of the use of DBS
and MCS was quite low, as would be expected given the current lack of funding for these treatments in
the NHS. Most responders thought both SCS and DRG stimulation to be either mostly or sometimes
effective for reducing PLP. Although neurosurgeons were split in their opinions on how frequently DBS is
effective, most considered MCS to rarely be effective. Most clinicians thought that a randomised trial
design was viable to study neuromodulation therapies, although recruiting enough participants was raised
as a concern. Pain physicians most wanted to see SCS and DRG stimulation studied in a RCT, whereas
neurosurgeons most wanted to see DRG stimulation and DBS studied in a RCT.
DOI: 10.3310/hta22620 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 62
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
75

Chapter 4 Discussion
Statement of principal findings
For non-invasive neurostimulation treatments, results from a good-quality randomised trial29 suggest
short-term benefits of rTMS in reducing PLP but not in reducing anxiety or depression. Small randomised
trials of tDCS30,45 suggest only the possibility of modest, short-term reductions in PLP. Both of these
interventions appear safe, but only larger trials with longer follow-up periods will resolve the considerable
uncertainty about their true potential for treating PLP.
For invasive neurostimulation treatments – DBS, MCS, SCS and DRG stimulation – all the available evidence
was derived from small, uncontrolled group studies or case reports. Although several studies reported results
that appeared impressive in the short term (many patients had reductions in PLP sufficient to warrant
permanent implantation), the effects diminished over time in some patients, with implants sometimes having
to be removed. Most studies did not have follow-up data beyond 2 to 3 years, although it is evident that
some patients still derived worthwhile benefits at these time points. Nevertheless, results from uncontrolled
studies are inherently unreliable and, aside from the problems with interpreting results that arise from not
having control data, many of these studies had other important methodological and/or reporting limitations.
Few studies recruited patients prospectively and consecutively. In terms of outcomes, many studies focused
on evaluating only pain intensity, using a visual analogue or numerical rating scale, and did not evaluate pain
frequency or duration. Although several studies used the McGill Pain Questionnaire (MPQ) – which utilises
information on more descriptive, qualitative aspects of pain – in many of them, results were not presented.
Few studies reported data on quality-of-life outcomes, which are very important when evaluating effects on
chronic pain. The consequences of these methodological and reporting limitations are that the results and
conclusions of most of these studies should not be considered robust. Given that invasive neuromodulation
is often used for only severe PLP and often as a late treatment option, the applicability of the results to a
broader chronic PLP population is limited. Therefore, there is still much uncertainty as to which neurostimulation
treatments are best for treating chronic PLP.
Although we identified numerous epidemiological studies, much of the evidence on prognostic factors for
the development of chronic PLP had important limitations. The longitudinal studies we identified were
quite small with limited follow-up periods; none addressed outcomes such as depression, anxiety and
quality of life, and most patients had quite mild PLP. Both pre-amputation pain and early PLP intensity
appear to be good predictors of chronic PLP up to 2 years after amputation. Neither level of amputation
nor early stump pain seem to be correlated with PLP intensity at later follow-ups. We also identified many
cross-sectional studies, which were useful for providing estimates of disease prevalence. Results suggested
that the proportion of chronic PLP patients with severe PLP lies between 30% and 40%, whereas the
proportion with moderate PLP is around 25%. From the studies reporting data on how chronic PLP
affects patients’ daily lives, it appears that around 25% of chronic PLP patients find their PLP to be either
moderately or severely limiting or bothersome. Much variation was reported across studies regarding the
frequency and duration of PLP attacks.
Our survey of the views of NHS clinicians indicated that SCS seems to be the most frequently used
neurostimulation therapy: around three-quarters of both pain physicians and neurosurgeons indicated that
their patients usually or sometimes use SCS. DRG stimulation is also frequently used. The prevalence of the use
of DBS and MCS was quite low, as would be expected given the current lack of funding for these treatments
in the NHS. The survey results also indicated a very high use of pharmacological treatments. TENS was not
thought to be very effective by most clinicians, although most considered cognitive–behavioural therapy to be
at least sometimes effective and most neurosurgeons considered acupuncture to be sometimes effective for
reducing chronic PLP. Most responders considered both SCS and DRG stimulation to be either mostly or
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sometimes effective. Although neurosurgeons were split in their opinions on how frequently DBS is effective,
most considered MCS to rarely be effective. A large majority of clinicians thought that a RCT design was viable
to study neurostimulation therapies, although recruiting enough participants was raised as a concern. Pain
physicians most wanted to see SCS and DRG stimulation studied in a RCT, whereas neurosurgeons most
wanted to see DRG stimulation and DBS studied in a RCT.
Strengths and limitations of the assessment
This study was designed to be broad in scope because we anticipated a sparse evidence base. We
conducted a systematic review of epidemiology studies in addition to a systematic review of effectiveness
studies, which was not restricted by study design for the invasive therapy studies. Moreover, these reviews
were augmented by a survey of relevant NHS clinicians. We adopted this approach in order to provide
further data to best inform our recommendations for future research.
The systematic reviews were undertaken using robust and transparent methods. The bibliographic database
searches were comprehensive, allowing identification of all relevant studies. Searches were also made to
identify any unpublished studies. The possibility of publication or language biases affecting the review was,
therefore, minimised. Similarly, the possibility of reviewer errors and biases affecting our review was reduced
by duplicating review processes, such as study eligibility screening. Thorough risk-of-bias evaluations were
made of the RCTs, and the single-group studies were evaluated on key aspects of study design. The sample
for our NHS survey was large and diverse enough to be representative of NHS staff who treat PLP using
neurostimulation treatments. The survey was circulated via two specialist e-mailing lists that were known
to the clinicians in the review team. Our estimates are that there are approximately 30 neurostimulation
centres in the UK (we had responses from 30 different hospitals), and that there are around 10–20 relevant
neurosurgeons (11 neurosurgeons responded). Therefore, we think that the survey results are broadly
representative of the views and practices of NHS clinicians.
The main limitation of the systematic review was the evidence that was identified. The RCTs were small,
with short-term data. The studies of invasive treatments were small, and lacked control groups; few studies
recruited patients prospectively and consecutively. For the epidemiology studies, although several aspects
of study quality, such as participation rates, were recorded and discussed in the review, this was done only
informally, which is a limitation. Although a number of relevant assessment tools exist, there is a need for
agreement on critical elements for assessing susceptibility to bias in epidemiology studies, and to develop
appropriate evaluation tools.119
Future research
Study design
The lack of controlled studies of invasive treatments for PLP presents a problem for decision-makers.
Although controlled studies are needed, the viability of possibly relevant study designs warrants careful
thought. Although there have been no RCTs of invasive treatments in a PLP population, a RCT of DBS has
recently been published on patients with post-stroke pain syndrome.120 This double-blinded, crossover RCT
recruited 10 patients at a single centre in the USA. After implantation of DBS leads, patients were randomised
to active or sham DBS for a period of 3 months, followed by crossover to the other study intervention for
3 months. Patients then underwent an 18-month open-label phase of DBS. The primary end point was a
≥ 50% improvement on the Pain Disability Index. During the randomised phase of the trial, patients were
followed up at 1, 2 and 3 months after randomisation and crossover. One patient withdrew from the study
before randomisation. No statistically significant differences were found between active DBS and sham in
scores for the Pain Disability Index, VAS or the Sensory Pain Rating Index of the MPQ.
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In considering the viability of this study design for trialling DBS for chronic PLP, it is noteworthy that 36
of the initial cohort of 69 patients identified as potential participants declined consent to be screened for
eligibility. Of the 33 who did consent to eligibility screening, 13 did not meet the eligibility criteria, six did
not give consent for further study and four were lost to follow-up. Therefore, in this particular RCT of
DBS in patients with chronic pain, around seven potential participants had to be identified in order to
randomise one. Moreover, although it was encouraging that 9 of the 10 randomised patients completed
both blinded intervention phases (i.e. they were followed up for 6 months), four participants withdrew
consent prior to completing the open-label phase, leaving only five participants with 18-month data.
All of the RCTs in our review were of non-invasive treatments and all were small. Three had a crossover design
and two had a parallel-group design. The largest trial, reported by Malavera et al.,29 was a parallel-group trial
that recruited 54 PLP patients from one centre in Columbia, although over one-quarter of eligible patients
declined participation. Although we identified five relevant ongoing trials in our searches, the proposed
sample sizes are generally small and two are uncontrolled (single-group) studies; therefore, the results of these
five trials (if published) may have only a minor impact on resolving uncertainty about which neurostimulation
treatments are most effective.
It seems clear that strategies to maximise patient recruitment and retention are key. A randomised
crossover design is useful in this respect because fewer patients are needed when compared with a
parallel-group trial; this is because patients act as their own control in a crossover trial. Crossover trials may
also be more appealing than parallel-group trials to both patients and ethics committees because patients
are guaranteed to receive an active treatment (providing they can complete both phases). In parallel-group
trials, patients can experience ‘resentful demoralisation’ if they think that they have been allocated an inert
or standard intervention, which may increase withdrawal rates. If a particular neurostimulation therapy
produces a clear sensation in the user, the use of sham stimulation, using parameters sufficient to give a
subtherapeutic sensation, should ensure that patients are adequately blinded in a crossover trial. Blinding
of caregivers and evaluators has been raised as an important design issue.121 The use of crossover designs
is often not a viable option in clinical research but they are viable in this area of research. This is because
chronic PLP is a stable condition and the effects of neurostimulation therapies are reversible (i.e. therapies
can be turned on and off). Although the duration of the carry-over effects of neurostimulation are
unknown with any precision, they are not thought to exceed several days at most.
Another study design that could be considered in a chronic PLP population, and that has similarities to a
crossover trial, is the N-of-1 trial design. The difference between the designs is that N-of-1 trials study
single participants, who typically receive more than one ‘cycle’ of treatments. Consequently, the unit of
randomisation is the treatment order within a treatment cycle for a patient. In a crossover trial, the patient
is the unit of randomisation, with one cycle of treatment normally given.122 The N-of-1 design has been
used to study DBS for neuropathic pain using five ‘pairs of treatments’: the stimulator being turned on
and off.83 N-of-1 trials are a very efficient and less costly way to gain insights into comparative treatment
effectiveness in a range of patients. Although they are most often used to derive comparative data for
different active treatments in single patients, in chronic PLP neurostimulation research they are more likely
to be used to compare the impact of several on/off phases. Furthermore, it is possible to meta-analyse data
from multiple N-of-1 trials investigating the same sets of interventions, which can be useful in identifying
clinical characteristics that are predictors of treatment response.123
Recruitment and retention of participants in a trial might be maximised by using eligibility criteria that
specify thresholds for PLP (e.g. a minimum mean VAS score of 5 on a 0–10 scale) and quality of life,
which reflect the subgroup of chronic PLP patients most in need of intervention. Eligible patients should
have tried and failed other relevant interventions from earlier in the treatment pathway. If recruitment is
anticipated to be the major obstacle, a prospective observational database or registry study could be
considered. Although this approach should maximise patient numbers, its results would inherently be
subject to uncertainty owing to confounding. It should be acknowledged that RCTs that do not recruit
enough participants may also produce unreliable results, being prone to chance effects. In the UK,
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neuromodulation registries exist for SCS and DBS. A hybrid design might also be practicable, whereby
N-of-1 trials are incorporated into clinical databases or registries, ensuring consistent approaches in patient
selection, interventions, outcome measures and data collection.
Regardless of the study design adopted, a collaborative approach between rehabilitation physicians
and implanting physicians will be important. Long-term assessment would also be needed, particularly of
quality-of-life outcomes and broader assessments of pain that go beyond pain intensity alone (such as the
MPQ).124 Long-term assessments would also provide valuable data on the development of tolerance of
neurostimulation therapy, about which little is known in the chronic PLP population. Both short- and
long-term data on adjustment of intervention parameters will be required, as will safety data. Concurrent
economic evaluation of therapies should be strongly considered in any future study of effectiveness.
Because learning curves can have an important impact on surgery study outcomes, it is recommended that
research studies are conducted at established centres with experienced surgeons.
Categorising and interpreting pain data
Many of the effectiveness studies in our review used thresholds to categorise treatment success, such as a
50% or a greater reduction in pain. Such thresholds may be quite arbitrary and not necessarily evidence-
based. Similarly, some of the epidemiology studies also categorised PLP as being mild, moderate or severe,
based on pain score. However, there is evidence suggesting that the cut-off scores used for these types of
categorisations, derived from research on patients with cancer pain, may not be optimal for studying
PLP.125
In many areas of pain research, studies are conducted to determine ‘minimum clinically important
differences’ (MCIDs): the smallest improvement in pain score perceived by patients as being beneficial.
‘Substantial’ clinically relevant differences are also sometimes used to interpret results of studies of
effectiveness. Determination of MCID for chronic PLP would help with interpreting results of efficacy
studies. A systematic review of 37 empirical studies that estimated MCID in acute pain found both wide
variation in MCIDs (8–40 mm on a 100-mm scale) and that baseline pain was strongly associated with
absolute, but not relative, MCID (patients with higher baseline pain needed more pain reduction to
perceive relief).126 The authors concluded that MCID is context-specific and potentially misguiding if
determined, applied or interpreted inappropriately. Even more relevant to future studies of chronic PLP,
the authors stated that they were due to publish a systematic review of the MCID in chronic pain, which
indicated similar issues of high study variability. For many conditions, MCIDs have also been calculated for
quality-of-life outcomes.127,128
Quality-of-life measures
Careful thought should also be given to the type of quality-of-life assessment tool used. The limited scope
and content of generic health-related quality-of-life measures may mean that, for some conditions, generic
tools may not be sensitive enough to detect meaningful changes resulting from treatment. However,
generic measures are useful in other ways: for example, in allowing easier comparison of results across
different patient groups. Generic and specific quality-of-life dimensions may be assessed simultaneously.
For patients with chronic pain, a pain and discomfort module has been developed to increase the
specificity and sensitivity of the generic core WHOQOL-100 (World Health Organization’s Quality of Life –
100 questions) instrument. This was done because the pain and discomfort facet in the original instrument
was found to under-represent the impact of chronic pain on quality of life. The module relates most
strongly to the physical, psychological and level-of-independence domains, and less to social relationships,
the environment or spirituality.129
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Conclusions
The studies of the efficacy, effectiveness and safety of neurostimulation treatments do not provide robust,
reliable results, largely owing to a combination of study design and reporting limitations, small sample sizes
and short follow-up periods. Consequently, there is much uncertainty about which neurostimulation
treatments are best for treating chronic PLP, hindering informed treatment decisions in clinical practice.
Many of the epidemiological studies that included chronic PLP patients also yielded limited data, although
they did indicate that PLP that substantially affects quality of life is not a rare condition among amputees.
Although these data, along with the views of NHS clinicians – derived from our survey – suggest that
recruitment to a randomised trial may be viable, there are credible concerns that recruitment and retention
might be problematic. Randomised crossover or randomised N-of-1 trial designs may be the most viable
approaches. An alternative study design could be a prospective registry study that incorporates N-of-1
trials. Among the NHS clinicians responding to our survey, SCS, DRG stimulation and DBS were the
interventions most frequently chosen for evaluation in RCTs. Regardless of the study design adopted,
long-term evaluation of quality-of-life outcomes is important, as are broader assessments of pain that go
beyond pain intensity alone.
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